<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>BloodðŸ©¸Doctor | CLL & Chronic B-cell Disorders</title>
<link rel="preconnect" href="https://fonts.googleapis.com"/>
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin/>
<link href="https://fonts.googleapis.com/css2?family=Fraunces:opsz,wght@9..144,500;9..144,600;9..144,700&family=Source+Sans+3:wght@300;400;500;600;700&family=IBM+Plex+Mono:wght@400;500;600&display=swap" rel="stylesheet"/>
<style>
:root{--bg-ivory:#f7f4ef;--surface:#fff;--ink-deep:#102a43;--ink-body:#243b53;--teal:#006d77;--teal-soft:#83c5be;--amber:#e09f3e;--cranberry:#b23a48;--sage:#2a9d8f;--border:#d9e2ec;--shadow:0 24px 48px rgba(16,42,67,.12);--radius:20px}
*{box-sizing:border-box;margin:0}
html{scroll-behavior:smooth}
body{font-family:'Source Sans 3',system-ui,sans-serif;color:var(--ink-body);background:var(--bg-ivory);line-height:1.6}
h1,h2,h3,h4{font-family:'Fraunces',serif;color:var(--ink-deep)}
a{color:inherit;text-decoration:none}
button{font-family:inherit;cursor:pointer}
code,.mono{font-family:'IBM Plex Mono',monospace}
.page{min-height:100vh}
/* HERO */
.hero{position:relative;padding:40px 6vw 60px;overflow:hidden;background:linear-gradient(135deg,#f7f4ef 0%,#e8f4f3 50%,#f7f4ef 100%)}
.hero::before{content:'';position:absolute;width:500px;height:500px;border-radius:50%;background:radial-gradient(circle,rgba(0,109,119,.18) 0%,transparent 70%);right:-180px;top:-200px}
.hero::after{content:'';position:absolute;width:400px;height:400px;border-radius:50%;background:radial-gradient(circle,rgba(224,159,62,.15) 0%,transparent 70%);left:-120px;bottom:-180px}
.nav{display:flex;align-items:center;justify-content:space-between;position:relative;z-index:1;flex-wrap:wrap;gap:12px}
.brand{font-size:1.5rem;font-weight:700;color:var(--teal)}
.brand-sub{font-size:.85rem;color:var(--ink-body);opacity:.7}
.nav-pills{display:flex;gap:10px;flex-wrap:wrap}
.pill{padding:7px 14px;border-radius:999px;background:rgba(0,109,119,.08);font-size:.82rem;font-weight:600;color:var(--teal)}
.hero-grid{margin-top:48px;display:grid;grid-template-columns:1.2fr 1fr;gap:36px;align-items:center;position:relative;z-index:1}
.hero-copy .tag{display:inline-block;padding:6px 14px;border-radius:999px;background:rgba(0,109,119,.1);font-size:.8rem;font-weight:600;color:var(--teal);margin-bottom:16px}
.hero-copy h1{font-size:clamp(2rem,3.8vw,3.6rem);line-height:1.08;margin-bottom:14px}
.hero-copy p{font-size:1.05rem;color:var(--ink-body);opacity:.78;margin-bottom:24px;max-width:560px}
.cta-row{display:flex;gap:12px;flex-wrap:wrap}
.cta-primary{background:var(--teal);color:#fff;border:none;padding:14px 28px;border-radius:999px;font-weight:600;font-size:.95rem;box-shadow:0 12px 28px rgba(0,109,119,.25);transition:transform .2s,box-shadow .2s}
.cta-primary:hover{transform:translateY(-2px);box-shadow:0 16px 36px rgba(0,109,119,.32)}
.cta-outline{background:transparent;color:var(--teal);border:2px solid var(--teal);padding:12px 24px;border-radius:999px;font-weight:600;font-size:.9rem;transition:all .2s}
.cta-outline:hover{background:var(--teal);color:#fff}
.hero-panel{background:var(--surface);border-radius:var(--radius);padding:24px;box-shadow:var(--shadow)}
.stat-grid{display:grid;gap:12px;margin-top:14px}
.stat{display:flex;justify-content:space-between;padding:12px 14px;border-radius:14px;background:var(--bg-ivory);font-size:.92rem}
.stat strong{color:var(--teal);font-family:'IBM Plex Mono',monospace}
/* STICKY NAV */
.sticky-nav{position:sticky;top:0;z-index:100;background:rgba(247,244,239,.95);backdrop-filter:blur(10px);border-bottom:1px solid var(--border);padding:10px 6vw;display:flex;gap:8px;overflow-x:auto;-webkit-overflow-scrolling:touch}
.sticky-nav a{white-space:nowrap;padding:8px 14px;border-radius:999px;font-size:.82rem;font-weight:600;color:var(--ink-body);transition:all .15s}
.sticky-nav a:hover,.sticky-nav a.active{background:var(--teal);color:#fff}
/* SECTIONS */
.section{padding:56px 6vw}
.section-title{font-size:1.9rem;margin-bottom:10px}
.section-sub{color:var(--ink-body);opacity:.72;max-width:780px;margin-bottom:24px}
/* MODULES */
.module{margin-top:36px;padding:28px;border-radius:var(--radius);background:var(--surface);box-shadow:var(--shadow)}
.module-head{display:flex;justify-content:space-between;align-items:center;flex-wrap:wrap;gap:12px;margin-bottom:18px}
.module-head h3{font-size:1.5rem}
.module-tag{padding:6px 14px;border-radius:999px;font-size:.8rem;font-weight:600}
.tag-dx{background:rgba(0,109,119,.1);color:var(--teal)}
.tag-core{background:rgba(42,157,143,.1);color:var(--sage)}
.tag-mol{background:rgba(224,159,62,.12);color:#b87a20}
.tag-prog{background:rgba(178,58,72,.08);color:var(--cranberry)}
.tag-tx{background:rgba(0,109,119,.1);color:var(--teal)}
.tag-comp{background:rgba(178,58,72,.1);color:var(--cranberry)}
.tag-diff{background:rgba(42,157,143,.1);color:var(--sage)}
.tag-fig{background:rgba(224,159,62,.1);color:#b87a20}
.module-grid{display:grid;grid-template-columns:repeat(2,1fr);gap:18px}
.card{border-radius:16px;padding:18px;background:var(--bg-ivory);display:grid;gap:10px}
.card h4{font-size:1.05rem}
.card p,.card li{color:var(--ink-body);line-height:1.65;font-size:.92rem}
.card ul{padding-left:18px}
.card.deep{background:#f0faf9;border:1px solid rgba(0,109,119,.1)}
/* CALLOUTS */
.callout{margin-top:16px;border-radius:14px;padding:14px 16px;display:grid;gap:6px}
.callout-label{text-transform:uppercase;font-size:.72rem;font-weight:700;letter-spacing:.08em}
.callout-text{font-size:.9rem;line-height:1.6}
.callout.high-yield{background:#fff5e6;border-left:4px solid var(--amber)}
.callout.high-yield .callout-label{color:var(--amber)}
.callout.pitfall{background:#fdf0f1;border-left:4px solid var(--cranberry)}
.callout.pitfall .callout-label{color:var(--cranberry)}
.callout.pearl{background:#e8f7f5;border-left:4px solid var(--sage)}
.callout.pearl .callout-label{color:var(--sage)}
.callout.red-flag{background:#fce8ea;border-left:4px solid #8b1a2b}
.callout.red-flag .callout-label{color:#8b1a2b}
.callout.molecular{background:#ecf9f7;border-left:4px solid var(--teal)}
.callout.molecular .callout-label{color:var(--teal)}
/* TABLES */
.table-wrap{overflow-x:auto;margin-top:10px}
table{width:100%;border-collapse:collapse;font-size:.85rem}
th,td{text-align:left;padding:10px 12px;border-bottom:1px solid var(--border);vertical-align:top}
th{background:rgba(0,109,119,.06);color:var(--ink-deep);font-weight:700;white-space:nowrap}
/* FLOW STEPS */
.flow{display:grid;gap:10px;margin-top:10px}
.flow-step{background:#f3f6f8;border-radius:12px;padding:12px 14px;display:flex;align-items:center;gap:12px;font-size:.9rem}
.flow-num{min-width:28px;height:28px;border-radius:50%;background:var(--teal);color:#fff;display:flex;align-items:center;justify-content:center;font-weight:700;font-size:.85rem}
/* ALGORITHM */
.algo{display:grid;gap:12px;margin-top:14px}
.algo-box{padding:16px;border-radius:14px;text-align:center;font-size:.88rem;font-weight:600}
.algo-decide{background:#fff5e6;border:2px solid var(--amber);color:var(--ink-deep)}
.algo-action{background:#e8f7f5;border:2px solid var(--sage);color:var(--ink-deep)}
.algo-warn{background:#fce8ea;border:2px solid var(--cranberry);color:var(--ink-deep)}
.algo-arrow{text-align:center;font-size:1.4rem;color:var(--teal);font-weight:700}
.algo-row{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:12px}
/* DETAILS */
details{border-radius:14px;border:1px solid var(--border);padding:12px 14px;background:var(--surface);margin-top:12px}
details summary{cursor:pointer;font-weight:600;font-size:.92rem}
details[open] summary{margin-bottom:10px}
/* QUIZ */
.quiz-zone{background:var(--surface);border-radius:var(--radius);padding:28px;box-shadow:var(--shadow);margin-top:36px}
.quiz-tabs{display:flex;gap:8px;margin-bottom:18px}
.quiz-tab{padding:10px 20px;border-radius:999px;border:2px solid var(--teal);background:transparent;color:var(--teal);font-weight:600;font-size:.9rem;transition:all .15s}
.quiz-tab.active{background:var(--teal);color:#fff}
.quiz-progress{height:6px;background:var(--border);border-radius:99px;margin-bottom:18px;overflow:hidden}
.quiz-progress-bar{height:100%;background:var(--teal);border-radius:99px;transition:width .3s}
.q-card{background:var(--bg-ivory);border-radius:16px;padding:20px;margin-bottom:14px}
.q-stem{font-weight:600;font-size:.95rem;margin-bottom:14px;line-height:1.5}
.q-meta{display:flex;gap:8px;margin-bottom:10px;flex-wrap:wrap}
.q-meta span{font-size:.72rem;padding:4px 10px;border-radius:999px;font-weight:600}
.q-topic{background:rgba(0,109,119,.1);color:var(--teal)}
.q-diff-easy{background:rgba(42,157,143,.1);color:var(--sage)}
.q-diff-medium{background:rgba(224,159,62,.12);color:#b87a20}
.q-diff-hard{background:rgba(178,58,72,.1);color:var(--cranberry)}
.q-options{display:grid;gap:8px}
.q-opt{display:flex;align-items:flex-start;gap:10px;padding:12px 14px;border-radius:12px;border:2px solid var(--border);background:var(--surface);cursor:pointer;font-size:.9rem;transition:all .15s;text-align:left;width:100%}
.q-opt:hover:not(.answered){border-color:var(--teal);background:rgba(0,109,119,.03)}
.q-opt.selected{border-color:var(--teal);background:rgba(0,109,119,.05)}
.q-opt.correct{border-color:var(--sage);background:rgba(42,157,143,.08)}
.q-opt.incorrect{border-color:var(--cranberry);background:rgba(178,58,72,.06)}
.q-opt.answered{cursor:default}
.q-opt-letter{min-width:28px;height:28px;border-radius:50%;background:var(--border);display:flex;align-items:center;justify-content:center;font-weight:700;font-size:.8rem;flex-shrink:0}
.q-feedback{margin-top:12px;padding:14px;border-radius:12px;font-size:.88rem;line-height:1.55;display:none}
.q-feedback.show{display:block}
.q-feedback.correct-fb{background:rgba(42,157,143,.08);border:1px solid var(--sage)}
.q-feedback.incorrect-fb{background:rgba(178,58,72,.06);border:1px solid var(--cranberry)}
/* RESULTS */
.results-card{background:var(--surface);border-radius:var(--radius);padding:28px;box-shadow:var(--shadow);text-align:center;display:none}
.results-card.show{display:block}
.results-score{font-size:3rem;font-weight:700;font-family:'Fraunces',serif;color:var(--teal)}
.results-award{font-size:1.5rem;margin:10px 0}
.results-grid{display:grid;grid-template-columns:repeat(5,1fr);gap:14px;margin:20px 0}
.results-stat{padding:14px;border-radius:14px;background:var(--bg-ivory)}
.results-stat .label{font-size:.78rem;color:var(--ink-body);opacity:.7}
.results-stat .value{font-size:1.4rem;font-weight:700;color:var(--teal);font-family:'IBM Plex Mono',monospace}
/* FOOTER */
.footer{padding:28px 6vw 40px;background:var(--ink-deep);color:rgba(255,255,255,.75);display:flex;justify-content:space-between;flex-wrap:wrap;gap:12px;font-size:.85rem}
.footer a{color:var(--teal-soft)}
/* UTILITY */
.simplify .deep,.simplify details,.simplify .table-wrap{display:none}
.hidden{display:none!important}
/* RESPONSIVE */
@media(max-width:980px){.hero-grid,.module-grid{grid-template-columns:1fr}.results-grid{grid-template-columns:repeat(3,1fr)}}
@media(max-width:600px){.results-grid{grid-template-columns:repeat(2,1fr)}}
@media(max-width:720px){.hero{padding:30px 5vw 48px}.section{padding:40px 5vw}.nav{flex-direction:column;align-items:flex-start}}
/* REDUCED MOTION */
@media(prefers-reduced-motion:reduce){*{animation:none!important;transition:none!important}}
/* FADE IN */
@keyframes fadeUp{from{opacity:0;transform:translateY(18px)}to{opacity:1;transform:translateY(0)}}
.module{animation:fadeUp .5s ease both}
</style>
</head>
<body>
<div class="page" id="top">

<!-- HERO -->
<header class="hero">
<nav class="nav">
<div><div class="brand">BloodðŸ©¸Doctor</div><div class="brand-sub">By Dr Abdul Mannan FRCPath FCPS</div></div>
<div class="nav-pills">
<span class="pill">CLL Learning Hub</span>
<span class="pill">blooddoctor.co@gmail.com</span>
</div>
</nav>
<div class="hero-grid">
<div class="hero-copy">
<div class="tag">Chronic B-cell Disorders &middot; Interactive Learning</div>
<h1>Chronic Lymphocytic Leukaemia and Chronic B-cell Lymphoproliferative Disorders</h1>
<p>High-yield diagnosis, risk stratification, and treatment pathways for trainees. Master CLL and its mimics with structured modules and exam-grade assessments.</p>
<div class="cta-row">
<button class="cta-primary" onclick="document.getElementById('mod-overview').scrollIntoView({behavior:'smooth'})">Start Learning</button>
<button class="cta-outline" onclick="document.getElementById('quiz-zone').scrollIntoView({behavior:'smooth'})">Take MCQ Challenge</button>
<button class="cta-outline" onclick="startEMQ()">Take EMQ Challenge</button>
</div>
</div>
<div class="hero-panel">
<div style="font-weight:700;font-size:1.1rem;color:var(--ink-deep)">Quick metrics</div>
<div class="stat-grid">
<div class="stat"><span>Exam-grade questions</span><strong>65</strong></div>
<div class="stat"><span>Clinical algorithms</span><strong>3</strong></div>
<div class="stat"><span>High-yield tables</span><strong>8+</strong></div>
<div class="stat"><span>Differential disorders</span><strong>7</strong></div>
</div>
</div>
</div>
</header>

<!-- STICKY NAV -->
<nav class="sticky-nav" id="stickyNav">
<a href="#mod-overview">Overview</a>
<a href="#mod-dx">Diagnosis</a>
<a href="#mod-mol">Molecular</a>
<a href="#mod-prog">Prognosis</a>
<a href="#mod-tx">Treatment</a>
<a href="#mod-comp">Complications</a>
<a href="#mod-other">Other Disorders</a>
<a href="#mod-fig">Figures</a>
<a href="#quiz-zone">Quiz Zone</a>
<a href="#mod-bib">Bibliography</a>
</nav>

<main class="section" id="app">

<!-- CONTROLS -->
<div style="display:flex;gap:14px;align-items:center;flex-wrap:wrap;background:var(--surface);border-radius:14px;padding:14px 16px;box-shadow:var(--shadow);margin-bottom:28px">
<strong>Controls</strong>
<button class="cta-outline" style="padding:8px 16px;font-size:.82rem" id="simplifyToggle" onclick="document.getElementById('app').classList.toggle('simplify');this.textContent=this.textContent==='Simplify view'?'Full view':'Simplify view'">Simplify view</button>
<input style="flex:1;min-width:200px;border:1px solid var(--border);border-radius:999px;padding:10px 14px;font-size:.88rem" id="searchBox" placeholder="Search modules by keyword..." oninput="filterModules(this.value)"/>
</div>

<!-- MODULE 1: OVERVIEW / CLASSIFICATION -->
<section class="module" id="mod-overview">
<div class="module-head"><h3>Module 1: Classification & Diagnostic Approach</h3><span class="module-tag tag-dx">Diagnosis</span></div>
<div class="module-grid">
<div class="card">
<h4>Chronic B-cell Disorders with Leukaemic Expression</h4>
<ul>
<li><strong>CLL / SLL / MBL</strong> &mdash; the CLL spectrum</li>
<li><strong>SMZL</strong> &mdash; Splenic marginal zone lymphoma</li>
<li><strong>HCL</strong> &mdash; Hairy-cell leukaemia</li>
<li><strong>Splenic B-cell lymphoma/leukaemia with prominent nucleoli</strong> (historically HCL variant)</li>
<li><strong>Non-nodal leukaemic MCL</strong> &mdash; Mantle cell lymphoma</li>
<li><strong>LPL / WM</strong> &mdash; Lymphoplasmacytic lymphoma / Waldenstr&ouml;m</li>
<li><strong>SDRPL</strong> &mdash; Splenic diffuse red pulp small B-cell lymphoma</li>
</ul>
</div>
<div class="card">
<h4>Diagnostic Sequence</h4>
<div class="flow">
<div class="flow-step"><span class="flow-num">1</span>Confirm persistent lymphocytosis (&gt;5&times;10<sup>9</sup>/L for &ge;3 months)</div>
<div class="flow-step"><span class="flow-num">2</span>Review blood film morphology with experienced haematopathologist</div>
<div class="flow-step"><span class="flow-num">3</span>Confirm clonality and immunophenotype (B or T, &kappa;/&lambda;)</div>
<div class="flow-step"><span class="flow-num">4</span>Add targeted genetics/FISH where differential exists</div>
<div class="flow-step"><span class="flow-num">5</span>Use tissue biopsy selectively (lymph node, marrow, spleen)</div>
</div>
</div>
</div>
<div class="card deep" style="margin-top:14px">
<h4>Diagnostic Marker Comparison Table</h4>
<div class="table-wrap">
<table>
<thead><tr><th>Disorder</th><th>CD5</th><th>CD23</th><th>CD200</th><th>CD103</th><th>CD123</th><th>Cyclin D1</th><th>MYD88</th><th>BRAF V600E</th></tr></thead>
<tbody>
<tr><td><strong>CLL</strong></td><td>+</td><td>+</td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&plusmn;</td><td>&minus;</td></tr>
<tr><td><strong>SMZL</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>HCL</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+</td><td>+</td><td>weak</td><td>&minus;</td><td>+</td></tr>
<tr><td><strong>Non-nodal MCL</strong></td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>LPL/WM</strong></td><td>&plusmn;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>+ (L265P)</td><td>&minus;</td></tr>
<tr><td><strong>SBCL-PN</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&plusmn;</td><td>+</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
<tr><td><strong>SDRPL</strong></td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td><td>&minus;</td></tr>
</tbody>
</table>
</div>
</div>
<!-- ALGORITHM 1: CLL DIAGNOSTIC ALGORITHM -->
<div style="margin-top:24px;padding:28px;border-radius:20px;background:linear-gradient(135deg,#f7f4ef 0%,#e8f4f3 50%,#f7f4ef 100%);border:2px solid var(--border);position:relative">
<div style="display:flex;align-items:center;gap:12px;margin-bottom:24px">
<div style="width:44px;height:44px;border-radius:50%;background:var(--teal);display:flex;align-items:center;justify-content:center">
<span style="color:#fff;font-size:1.3rem;font-weight:700">1</span>
</div>
<div>
<h4 style="font-size:1.25rem;margin:0;color:var(--ink-deep);font-family:'Fraunces',serif">CLL Diagnostic Algorithm</h4>
<span style="font-size:.78rem;color:var(--ink-body);opacity:.7">BloodðŸ©¸Doctor &middot; Dr Abdul Mannan FRCPath FCPS</span>
</div>
</div>

<!-- START NODE -->
<div style="display:flex;flex-direction:column;align-items:center;gap:0">
<div style="background:var(--surface);border:2px solid var(--teal);border-radius:14px;padding:16px 24px;text-align:center;font-size:.92rem;font-weight:600;color:var(--ink-deep);max-width:420px;width:100%;box-shadow:0 4px 12px rgba(0,109,119,.1)">
Lymphocytosis Detected on FBC
</div>

<!-- ARROW DOWN -->
<div style="display:flex;flex-direction:column;align-items:center;gap:0">
<div style="width:3px;height:28px;background:var(--teal)"></div>
<div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--teal)"></div>
</div>

<!-- DECISION 1: Persistent >3 months? -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:18px 22px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:380px;width:100%;transform:rotate(0deg);clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:120px;display:flex;align-items:center;justify-content:center;box-shadow:0 4px 16px rgba(224,159,62,.15)">
<span style="max-width:200px;display:block;line-height:1.4">Persistent &gt;3 months?</span>
</div>

<!-- BRANCH: YES / NO -->
<div style="display:flex;width:100%;max-width:700px;justify-content:center;gap:0;position:relative;margin-top:-2px">
<!-- LEFT BRANCH: NO -->
<div style="flex:1;display:flex;flex-direction:column;align-items:center;max-width:280px">
<div style="display:flex;align-items:center;gap:0">
<div style="width:60px;height:3px;background:var(--cranberry)"></div>
<div style="width:0;height:0;border-top:7px solid transparent;border-bottom:7px solid transparent;border-left:9px solid var(--cranberry)"></div>
</div>
<div style="background:rgba(178,58,72,.06);border:2px solid var(--cranberry);border-radius:12px;padding:12px 16px;text-align:center;font-size:.82rem;font-weight:600;color:var(--cranberry);margin-top:-6px;width:100%">
<div style="font-size:.7rem;font-weight:700;background:var(--cranberry);color:#fff;border-radius:999px;padding:2px 10px;display:inline-block;margin-bottom:6px">NO</div><br>
Reactive / Transient<br>
<span style="font-weight:400;font-size:.78rem;color:var(--ink-body)">Investigate other causes (infection, autoimmune, stress)</span>
</div>
</div>
<!-- CENTER ARROW DOWN: YES -->
<div style="flex:0 0 auto;display:flex;flex-direction:column;align-items:center;padding:0 12px">
<div style="font-size:.7rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 10px;display:inline-block;margin-bottom:4px">YES</div>
<div style="width:3px;height:24px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--sage)"></div>
</div>
<!-- RIGHT spacer -->
<div style="flex:1;max-width:280px"></div>
</div>

<!-- STEP: Immunophenotyping -->
<div style="background:var(--surface);border:2px solid var(--teal);border-radius:14px;padding:16px 24px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:420px;width:100%;box-shadow:0 4px 12px rgba(0,109,119,.1)">
Perform Immunophenotyping<br>
<span style="font-weight:400;font-size:.8rem;color:var(--ink-body)">(CD5, CD19, CD20, CD23, CD200, SmIg, FMC7)</span>
</div>

<!-- ARROW DOWN -->
<div style="display:flex;flex-direction:column;align-items:center;gap:0">
<div style="width:3px;height:28px;background:var(--teal)"></div>
<div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--teal)"></div>
</div>

<!-- DECISION 2: CLL Score 4-5? -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:18px 22px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:380px;width:100%;clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:120px;display:flex;align-items:center;justify-content:center;box-shadow:0 4px 16px rgba(224,159,62,.15)">
<span style="max-width:200px;display:block;line-height:1.4">CLL Score 4&ndash;5?</span>
</div>

<!-- BRANCH: YES / NO -->
<div style="display:flex;width:100%;max-width:800px;justify-content:center;gap:24px;position:relative;margin-top:-2px">
<!-- LEFT: Score <4 -->
<div style="flex:1;display:flex;flex-direction:column;align-items:center;max-width:340px">
<div style="display:flex;align-items:center;gap:0;margin-bottom:8px">
<div style="width:40px;height:3px;background:var(--amber)"></div>
<div style="width:0;height:0;border-top:7px solid transparent;border-bottom:7px solid transparent;border-left:9px solid var(--amber)"></div>
</div>
<div style="font-size:.7rem;font-weight:700;background:var(--amber);color:#fff;border-radius:999px;padding:2px 10px;display:inline-block;margin-bottom:8px">SCORE &lt;4</div>
<div style="background:#fff5e6;border:2px solid var(--amber);border-radius:14px;padding:14px 16px;text-align:center;font-size:.82rem;font-weight:600;color:var(--ink-deep);width:100%">
Consider Other Diagnoses<br>
<span style="font-weight:400;font-size:.78rem;color:var(--ink-body)">SMZL, HCL, MCL, LPL/WM</span>
</div>
<!-- Arrow down -->
<div style="width:3px;height:18px;background:var(--amber);margin:0 auto"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--amber);margin:0 auto"></div>
<div style="background:var(--surface);border:2px solid var(--amber);border-radius:12px;padding:12px 14px;text-align:center;font-size:.8rem;color:var(--ink-body);width:100%;margin-top:4px">
<strong>Additional Markers:</strong><br>
CD103, BRAF V600E, Cyclin D1, MYD88 L265P, Annexin A1
</div>
</div>

<!-- RIGHT: Score 4-5 -->
<div style="flex:1;display:flex;flex-direction:column;align-items:center;max-width:340px">
<div style="font-size:.7rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 10px;display:inline-block;margin-bottom:4px">SCORE 4&ndash;5</div>
<div style="width:3px;height:20px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--sage)"></div>

<!-- DECISION 3: B cells >=5? -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:14px 18px;text-align:center;font-size:.85rem;font-weight:600;color:var(--ink-deep);width:100%;clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:100px;display:flex;align-items:center;justify-content:center;box-shadow:0 4px 12px rgba(224,159,62,.1)">
<span style="max-width:180px;display:block;line-height:1.3;font-size:.82rem">B cells &ge;5&times;10&#8313;/L?</span>
</div>

<!-- Sub-branches -->
<div style="display:flex;width:100%;gap:12px;margin-top:-2px">
<!-- YES = CLL -->
<div style="flex:1;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 8px;margin-bottom:4px">YES</div>
<div style="width:3px;height:14px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--sage)"></div>
<div style="background:#e8f7f5;border:2.5px solid var(--sage);border-radius:14px;padding:14px;text-align:center;font-weight:700;font-size:.95rem;color:var(--sage);width:100%;box-shadow:0 4px 16px rgba(42,157,143,.15);margin-top:4px">
CLL
<div style="font-size:.75rem;font-weight:400;color:var(--ink-body);margin-top:4px">Proceed to staging &amp; molecular workup</div>
</div>
</div>
<!-- NO = MBL/SLL -->
<div style="flex:1;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--cranberry);color:#fff;border-radius:999px;padding:2px 8px;margin-bottom:4px">NO</div>
<div style="width:3px;height:14px;background:var(--cranberry)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--cranberry)"></div>
<div style="background:rgba(178,58,72,.05);border:2px solid var(--cranberry);border-radius:14px;padding:14px;text-align:center;font-weight:600;font-size:.85rem;color:var(--ink-deep);width:100%;margin-top:4px">
MBL or SLL
<div style="font-size:.75rem;font-weight:400;color:var(--ink-body);margin-top:4px">Check for tissue disease (adenopathy, organomegaly)</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<!-- END ALGORITHM 1 -->

<div class="callout pearl"><div class="callout-label">Clinical Pearl</div><div class="callout-text">In typical CLL with high lymphocyte count and classic phenotype, lymph node biopsy is NOT required. Reserve biopsy for atypical cases and suspected lymphoma.</div></div>
</section>

<!-- MODULE 2: CLL CORE -->
<section class="module" id="mod-core">
<div class="module-head"><h3>Module 2: CLL Core Concepts</h3><span class="module-tag tag-core">Core</span></div>
<div class="module-grid">
<div class="card">
<h4>Definition & CLL-SLL Continuum</h4>
<ul>
<li>CLL: &ge;5&times;10<sup>9</sup>/L monoclonal B cells in blood for &ge;3 months with typical immunophenotype (SmIg<sup>weak</sup>, CD5+, CD19+, CD20<sup>weak</sup>, CD23+, CD200+)</li>
<li>SLL: tissue-dominant disease (same phenotype) with blood B cells &lt;5&times;10<sup>9</sup>/L</li>
<li>MBL: &lt;5&times;10<sup>9</sup>/L clonal B cells, no adenopathy/organomegaly/symptoms</li>
<li>~90% present as CLL, ~10% as SLL</li>
</ul>
</div>
<div class="card">
<h4>Epidemiology & Clinical Features</h4>
<ul>
<li>Most frequent leukaemia in Western countries (~34% of all leukaemias)</li>
<li>M:F ratio 1.5&ndash;2:1; median age at diagnosis ~70 years</li>
<li>~80% diagnosed while asymptomatic (incidental finding)</li>
<li>Painless generalised lymphadenopathy (neck, axillae, inguinal)</li>
<li>Familial risk: 3&ndash;8x higher in first-degree relatives</li>
<li>Rare in Asian populations; remains rare in migrant populations</li>
</ul>
</div>
<div class="card deep">
<h4>Immune Dysfunction Profile</h4>
<ul>
<li><strong>Hypogammaglobulinaemia:</strong> affects ~25%, IgM falls first, then IgG, then IgA</li>
<li><strong>T-cell exhaustion:</strong> inverted CD4/CD8 ratio, increased PD-1/LAG-3/CTLA-4</li>
<li><strong>NK cell / ADCC defects</strong></li>
<li><strong>Monocyte and granulocyte dysfunction</strong></li>
<li><strong>Suboptimal vaccination responses</strong></li>
</ul>
</div>
<div class="card">
<h4>Laboratory Hallmarks</h4>
<ul>
<li>Elevated WBC with absolute lymphocytosis</li>
<li>Small mature lymphocytes with scanty cytoplasm</li>
<li>Smudge cells (Gumprecht cells) on blood film</li>
<li>Prolymphocytes 1&ndash;10% nearly always present when WBC &gt;30&times;10<sup>9</sup>/L</li>
<li>Prolymphocytes &gt;15% = accelerated/transforming CLL</li>
</ul>
</div>
</div>
<div class="callout high-yield"><div class="callout-label">High Yield</div><div class="callout-text">High WBC count alone does NOT mandate treatment in CLL. Treatment is only indicated for active/progressive disease.</div></div>
</section>

<!-- MODULE 3: MOLECULAR -->
<section class="module" id="mod-mol">
<div class="module-head"><h3>Module 3: Molecular & Cytogenetics Simplified</h3><span class="module-tag tag-mol">High Priority</span></div>
<div class="module-grid">
<div class="card deep">
<h4>IGHV Mutated vs Unmutated</h4>
<p><strong>Two biologic behaviours in one disease.</strong> Mutated IGHV (&lt;98% germline homology) = post-germinal centre origin, indolent biology, longer treatment-free interval, median survival &gt;15 years. Unmutated IGHV = pre-GC origin, aggressive kinetics, shorter survival (6&ndash;7 years historically).</p>
</div>
<div class="card deep">
<h4>del(13q) Isolated</h4>
<p><strong>Generally favourable biology.</strong> Present in 25&ndash;40% of cases. Associated with mutated IGHV, MYD88 mutations, miR-15a/miR-16 involvement. Median survival &gt;15 years when found as sole abnormality.</p>
</div>
<div class="card deep">
<h4>del(11q) / ATM</h4>
<p><strong>Higher-risk profile in CIT era.</strong> Present in 20&ndash;25%. Associated with unmutated IGHV, ATM mutations (30%), BIRC3 mutations. Historically shorter treatment-free survival. BCRi/BCL2i overcome poor prognostic significance.</p>
</div>
<div class="card deep">
<h4>del(17p) / TP53</h4>
<p><strong>Poor CIT response; pathway inhibitor preference.</strong> Present in 5&ndash;50% depending on disease stage. Usually accompanied by TP53 mutation on other allele. The most important predictor of CIT resistance. Must use BTKi or BCL2i. Median survival 3&ndash;6 years with CIT.</p>
</div>
<div class="card deep">
<h4>Complex Karyotype</h4>
<p><strong>Risk escalation marker.</strong> Defined as &gt;3 or &gt;5 aberrations. Found in 5&ndash;30%. Often includes TP53 mutations. Associated with clonal evolution and poorer outcomes even with targeted therapy.</p>
</div>
<div class="card deep">
<h4>BCR Signalling & Apoptosis Escape</h4>
<p><strong>Why BTKi and BCL2i work.</strong> CLL cells depend on BCR signalling for survival and proliferation &rarr; BTK inhibitors block this pathway. CLL cells overexpress BCL2 (antiapoptotic) &rarr; venetoclax directly triggers apoptosis. This explains the class-switch strategy in relapsed disease.</p>
</div>
</div>
<details>
<summary>Cytogenetic Correlation Table (Table 23.3)</summary>
<div class="table-wrap">
<table>
<thead><tr><th>Abnormality</th><th>Frequency</th><th>Biological</th><th>Clinical</th><th>Median Survival</th></tr></thead>
<tbody>
<tr><td>del(13q14) isolated</td><td>25&ndash;40%</td><td>Mutated IGHV, MYD88, miR15/16</td><td>Good prognosis</td><td>&gt;15 years</td></tr>
<tr><td>Trisomy 12</td><td>15&ndash;20%</td><td>Unmutated IGHV, NOTCH1, atypical morphology</td><td>Short treatment-free survival after CIT</td><td>~10 years</td></tr>
<tr><td>del(11q22-23)</td><td>20&ndash;25%</td><td>Unmutated IGHV, ATM/BIRC3 mutations</td><td>Short TFS; BCRi/BCL2i overcome</td><td>6&ndash;8 years</td></tr>
<tr><td>del(17p13.1)</td><td>5&ndash;50%</td><td>Unmutated IGHV, TP53, complex karyotype</td><td>CIT resistance; use pathway inhibitors</td><td>3&ndash;6 years</td></tr>
</tbody>
</table>
</div>
</details>
<div class="callout molecular"><div class="callout-label">Molecular Simplified</div><div class="callout-text">Think of IGHV status as the master switch: mutated = slow lane, unmutated = fast lane. TP53/del(17p) = CIT exit ramp &rarr; must use BTKi or BCL2i.</div></div>
</section>

<!-- MODULE 4: PROGNOSIS -->
<section class="module" id="mod-prog">
<div class="module-head"><h3>Module 4: Prognosis & Risk Stratification</h3><span class="module-tag tag-prog">Prognosis</span></div>
<div class="module-grid">
<div class="card deep">
<h4>Rai Staging</h4>
<div class="table-wrap">
<table>
<thead><tr><th>Stage</th><th>Features</th><th>Risk</th><th>Median Survival</th></tr></thead>
<tbody>
<tr><td>0</td><td>Lymphocytosis only</td><td>Low</td><td>&gt;15 years</td></tr>
<tr><td>I</td><td>+ Lymphadenopathy</td><td>Intermediate</td><td>~10 years</td></tr>
<tr><td>II</td><td>+ Spleen/liver enlargement</td><td>Intermediate</td><td>7&ndash;9 years</td></tr>
<tr><td>III</td><td>+ Anaemia (Hb &lt;110 g/L)</td><td>High</td><td>3&ndash;5 years</td></tr>
<tr><td>IV</td><td>+ Thrombocytopenia (&lt;100&times;10<sup>9</sup>/L)</td><td>High</td><td>3&ndash;5 years</td></tr>
</tbody>
</table>
</div>
</div>
<div class="card deep">
<h4>Binet Staging</h4>
<div class="table-wrap">
<table>
<thead><tr><th>Stage</th><th>Features</th><th>Median Survival</th></tr></thead>
<tbody>
<tr><td>A</td><td>&lt;3 lymphoid areas enlarged</td><td>&gt;15 years</td></tr>
<tr><td>B</td><td>&ge;3 lymphoid areas enlarged</td><td>7&ndash;9 years</td></tr>
<tr><td>C</td><td>Hb &lt;110 g/L and/or platelets &lt;100&times;10<sup>9</sup>/L</td><td>3&ndash;5 years</td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="module-grid" style="margin-top:14px">
<div class="card" style="background:#e8f7f5;border:2px solid var(--sage)">
<h4 style="color:var(--sage)">Good-Risk Pattern</h4>
<ul>
<li>Early stage (Binet A, Rai 0)</li>
<li>Mutated IGHV</li>
<li>Isolated del(13q)</li>
<li>Normal beta-2 microglobulin</li>
<li>Low blood lymphocyte count (&lt;15&times;10<sup>9</sup>/L)</li>
<li>Long LDT (&gt;12 months)</li>
</ul>
</div>
<div class="card" style="background:#fce8ea;border:2px solid var(--cranberry)">
<h4 style="color:var(--cranberry)">High-Risk Pattern</h4>
<ul>
<li>Advanced stage (Binet B/C, Rai I&ndash;IV)</li>
<li>Unmutated IGHV</li>
<li>del(17p)/TP53, del(11q), complex karyotype</li>
<li>Elevated beta-2 microglobulin</li>
<li>High blood lymphocyte count (&ge;15&times;10<sup>9</sup>/L)</li>
<li>Short LDT (&lt;12 months)</li>
</ul>
</div>
</div>
<div class="callout pearl"><div class="callout-label">Clinical Pearl</div><div class="callout-text">The CLL-IPI combines Rai stage, age, TP53, IGHV status and beta-2 microglobulin into four risk groups. However, it was developed for CIT-treated patients and poorly predicts outcomes on BTKi/BCL2i.</div></div>
</section>

<!-- MODULE 5: TREATMENT -->
<section class="module" id="mod-tx">
<div class="module-head"><h3>Module 5: Treatment Strategy</h3><span class="module-tag tag-tx">Treatment</span></div>
<div class="module-grid">
<div class="card">
<h4>When NOT to Treat: Active Surveillance</h4>
<p>Asymptomatic early-stage CLL (Binet A, Rai 0) without active disease features should be observed with periodic monitoring. Early treatment has NOT shown survival benefit.</p>
</div>
<div class="card">
<h4>Treatment Initiation Criteria</h4>
<ul>
<li>Hb &lt;110 g/L from marrow failure</li>
<li>Platelets &lt;100&times;10<sup>9</sup>/L from marrow failure</li>
<li>Massive (&ge;6 cm below costal margin) or progressive splenomegaly</li>
<li>Massive (&ge;10 cm) or progressive lymphadenopathy</li>
<li>Progressive lymphocytosis (&gt;50% increase in 2 months or LDT &lt;6 months)</li>
<li>Constitutional symptoms (B symptoms)</li>
<li>Refractory autoimmune cytopenia</li>
</ul>
</div>
</div>
<!-- ALGORITHM 2: CLL TREATMENT DECISION ALGORITHM (ENHANCED) -->
<div style="margin-top:24px;padding:28px;border-radius:20px;background:linear-gradient(135deg,#f7f4ef 0%,#e8f4f3 50%,#f7f4ef 100%);border:2px solid var(--border);position:relative;overflow-x:auto">
<div style="display:flex;align-items:center;gap:12px;margin-bottom:24px">
<div style="width:44px;height:44px;border-radius:50%;background:var(--teal);display:flex;align-items:center;justify-content:center">
<span style="color:#fff;font-size:1.3rem;font-weight:700">2</span>
</div>
<div>
<h4 style="font-size:1.25rem;margin:0;color:var(--ink-deep);font-family:'Fraunces',serif">CLL Treatment Decision Algorithm</h4>
<span style="font-size:.78rem;color:var(--ink-body);opacity:.7">BloodðŸ©¸Doctor &middot; Dr Abdul Mannan FRCPath FCPS</span>
</div>
</div>

<div style="display:flex;flex-direction:column;align-items:center;gap:0;min-width:320px">

<!-- ROW 1: START NODE -->
<div style="background:var(--surface);border:2.5px solid var(--teal);border-radius:14px;padding:16px 28px;text-align:center;font-size:.95rem;font-weight:700;color:var(--teal);max-width:380px;width:100%;box-shadow:0 6px 20px rgba(0,109,119,.12)">
CLL Diagnosed
</div>

<!-- Arrow down -->
<div style="display:flex;flex-direction:column;align-items:center"><div style="width:3px;height:24px;background:var(--teal)"></div><div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--teal)"></div></div>

<!-- ROW 2: DECISION DIAMOND - Active disease? -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:20px 24px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:380px;width:100%;clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:130px;display:flex;align-items:center;justify-content:center;box-shadow:0 4px 16px rgba(224,159,62,.15)">
<span style="max-width:220px;display:block;line-height:1.4">Active Disease<br>Criteria Met?</span>
</div>

<!-- ROW 3: YES / NO BRANCHES -->
<div style="display:flex;width:100%;max-width:860px;justify-content:center;gap:0;position:relative;margin-top:-2px">

<!-- LEFT BRANCH: NO = Watch & Wait -->
<div style="flex:0 0 auto;display:flex;align-items:flex-start;max-width:240px">
<div style="display:flex;flex-direction:column;align-items:center;width:100%">
<div style="display:flex;align-items:center;gap:0">
<div style="width:50px;height:3px;background:var(--sage)"></div>
<div style="width:0;height:0;border-top:7px solid transparent;border-bottom:7px solid transparent;border-left:9px solid var(--sage)"></div>
</div>
<div style="font-size:.68rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 10px;display:inline-block;margin:4px 0 6px">NO</div>
<div style="background:#e8f7f5;border:2.5px solid var(--sage);border-radius:14px;padding:16px;text-align:center;font-size:.88rem;font-weight:700;color:var(--sage);width:100%;box-shadow:0 4px 12px rgba(42,157,143,.1)">
Watch &amp; Wait
<div style="font-size:.75rem;font-weight:400;color:var(--ink-body);margin-top:6px;line-height:1.5">Monitor every 3&ndash;6 months<br>FBC, clinical exam, LDT</div>
</div>
</div>
</div>

<!-- CENTER: YES arrow continuing down -->
<div style="flex:0 0 auto;display:flex;flex-direction:column;align-items:center;padding:0 20px">
<div style="font-size:.68rem;font-weight:700;background:var(--amber);color:#fff;border-radius:999px;padding:2px 10px;display:inline-block;margin-bottom:4px">YES</div>
<div style="width:3px;height:28px;background:var(--amber)"></div>
<div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--amber)"></div>
</div>

<!-- RIGHT spacer -->
<div style="flex:0 0 auto;max-width:240px"></div>
</div>

<!-- ROW 4: Assess Biomarkers -->
<div style="background:var(--surface);border:2px solid var(--teal);border-radius:14px;padding:14px 22px;text-align:center;font-size:.88rem;font-weight:600;color:var(--ink-deep);max-width:440px;width:100%;box-shadow:0 4px 12px rgba(0,109,119,.08)">
Assess TP53/del(17p) + IGHV Mutation Status + Patient Fitness
</div>

<!-- Arrow down -->
<div style="display:flex;flex-direction:column;align-items:center"><div style="width:3px;height:24px;background:var(--teal)"></div><div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--teal)"></div></div>

<!-- ROW 5: DECISION DIAMOND - TP53? -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:18px 22px;text-align:center;font-size:.88rem;font-weight:600;color:var(--ink-deep);max-width:380px;width:100%;clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:120px;display:flex;align-items:center;justify-content:center;box-shadow:0 4px 16px rgba(224,159,62,.15)">
<span style="max-width:220px;display:block;line-height:1.3">del(17p) / TP53<br>Disrupted?</span>
</div>

<!-- ROW 6: THREE TREATMENT COLUMNS -->
<div style="display:flex;width:100%;max-width:920px;justify-content:center;gap:16px;margin-top:4px;flex-wrap:wrap">

<!-- COL 1: TP53 Disrupted (High Risk) -->
<div style="flex:1;min-width:240px;max-width:290px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--cranberry);color:#fff;border-radius:999px;padding:3px 12px;margin-bottom:4px">YES &mdash; TP53 DISRUPTED</div>
<div style="width:3px;height:16px;background:var(--cranberry)"></div>
<div style="width:0;height:0;border-left:7px solid transparent;border-right:7px solid transparent;border-top:9px solid var(--cranberry)"></div>
<div style="background:#fce8ea;border:2.5px solid var(--cranberry);border-radius:14px;padding:16px 14px;text-align:center;font-size:.84rem;font-weight:600;color:var(--ink-deep);width:100%;margin-top:4px;box-shadow:0 4px 12px rgba(178,58,72,.08)">
<div style="color:var(--cranberry);font-weight:700;font-size:.78rem;text-transform:uppercase;letter-spacing:.05em;margin-bottom:8px">High Risk</div>
<div style="font-weight:700;color:var(--cranberry)">BTKi Preferred</div>
<div style="font-size:.76rem;font-weight:400;color:var(--ink-body);margin-top:4px">Zanubrutinib or Acalabrutinib<br>(2nd-gen preferred over ibrutinib)</div>
<div style="margin:10px 0;padding:8px 0;border-top:1.5px dashed var(--cranberry);border-bottom:1.5px dashed var(--cranberry);font-size:.76rem;color:var(--ink-body)"><strong>OR</strong></div>
<div style="font-weight:600">Venetoclax + anti-CD20</div>
<div style="font-size:.72rem;font-weight:400;color:var(--ink-body);margin-top:4px;padding:6px;background:rgba(178,58,72,.06);border-radius:8px">Avoid CIT &mdash; CIT resistance expected</div>
</div>
</div>

<!-- COL 2: TP53 Intact + IGHV Mutated (Favourable) -->
<div style="flex:1;min-width:240px;max-width:290px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:3px 12px;margin-bottom:4px">NO + IGHV MUTATED</div>
<div style="width:3px;height:16px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:7px solid transparent;border-right:7px solid transparent;border-top:9px solid var(--sage)"></div>
<div style="background:#e8f7f5;border:2.5px solid var(--sage);border-radius:14px;padding:16px 14px;text-align:center;font-size:.84rem;font-weight:600;color:var(--ink-deep);width:100%;margin-top:4px;box-shadow:0 4px 12px rgba(42,157,143,.08)">
<div style="color:var(--sage);font-weight:700;font-size:.78rem;text-transform:uppercase;letter-spacing:.05em;margin-bottom:8px">Favourable</div>
<div style="font-weight:700;color:var(--sage)">Consider FCR</div>
<div style="font-size:.76rem;font-weight:400;color:var(--ink-body);margin-top:4px">Fit patients &lt;65 years<br>(curative potential in this subset)</div>
<div style="margin:10px 0;padding:8px 0;border-top:1.5px dashed var(--sage);border-bottom:1.5px dashed var(--sage);font-size:.76rem;color:var(--ink-body)"><strong>OR</strong></div>
<div style="font-weight:600">BTKi / Venetoclax + Obinutuzumab</div>
<div style="font-size:.72rem;font-weight:400;color:var(--ink-body);margin-top:4px;padding:6px;background:rgba(42,157,143,.06);border-radius:8px">Equally effective; preferred if not fit for FCR</div>
</div>
</div>

<!-- COL 3: TP53 Intact + IGHV Unmutated (Intermediate) -->
<div style="flex:1;min-width:240px;max-width:290px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--amber);color:#fff;border-radius:999px;padding:3px 12px;margin-bottom:4px">NO + IGHV UNMUTATED</div>
<div style="width:3px;height:16px;background:var(--amber)"></div>
<div style="width:0;height:0;border-left:7px solid transparent;border-right:7px solid transparent;border-top:9px solid var(--amber)"></div>
<div style="background:#fff5e6;border:2.5px solid var(--amber);border-radius:14px;padding:16px 14px;text-align:center;font-size:.84rem;font-weight:600;color:var(--ink-deep);width:100%;margin-top:4px;box-shadow:0 4px 12px rgba(224,159,62,.08)">
<div style="color:#b87a20;font-weight:700;font-size:.78rem;text-transform:uppercase;letter-spacing:.05em;margin-bottom:8px">Intermediate Risk</div>
<div style="font-weight:700;color:#b87a20">BTKi or Venetoclax + Obinutuzumab</div>
<div style="font-size:.76rem;font-weight:400;color:var(--ink-body);margin-top:4px">Pathway inhibitors preferred<br>over CIT in unmutated IGHV</div>
<div style="font-size:.72rem;font-weight:400;color:var(--ink-body);margin-top:8px;padding:6px;background:rgba(224,159,62,.08);border-radius:8px">Avoid FCR &mdash; short remissions expected</div>
</div>
</div>
</div>

<!-- FRAIL / ELDERLY CALLOUT -->
<div style="margin-top:18px;background:rgba(178,58,72,.04);border:2px dashed var(--cranberry);border-radius:14px;padding:14px 18px;display:flex;align-items:center;gap:14px;width:100%;max-width:700px">
<div style="min-width:36px;height:36px;border-radius:50%;background:var(--cranberry);display:flex;align-items:center;justify-content:center;flex-shrink:0">
<span style="color:#fff;font-size:1rem;font-weight:700">!</span>
</div>
<div style="font-size:.82rem;color:var(--ink-deep);line-height:1.5">
<strong style="color:var(--cranberry)">Frail / Elderly Patients:</strong> Chlorambucil + Obinutuzumab or low-dose ibrutinib. Venetoclax + Obinutuzumab also an option with careful TLS monitoring.
</div>
</div>

<!-- SEPARATOR LINE -->
<div style="width:100%;max-width:700px;height:2px;background:linear-gradient(90deg,transparent,var(--teal),transparent);margin:24px 0 8px;border-radius:2px"></div>
<div style="font-size:.82rem;font-weight:700;color:var(--teal);text-transform:uppercase;letter-spacing:.1em;margin-bottom:10px">Relapsed / Refractory Setting</div>

<!-- Arrow down -->
<div style="display:flex;flex-direction:column;align-items:center"><div style="width:3px;height:18px;background:var(--teal)"></div><div style="width:0;height:0;border-left:7px solid transparent;border-right:7px solid transparent;border-top:9px solid var(--teal)"></div></div>

<!-- DECISION: What was prior therapy? -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:14px 20px;text-align:center;font-size:.85rem;font-weight:600;color:var(--ink-deep);max-width:340px;width:100%;clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:100px;display:flex;align-items:center;justify-content:center">
<span style="max-width:200px;display:block;line-height:1.3;font-size:.82rem">What Was<br>Prior Therapy?</span>
</div>

<!-- RELAPSE COLUMNS -->
<div style="display:flex;width:100%;max-width:860px;gap:14px;flex-wrap:wrap;justify-content:center;margin-top:4px">

<!-- After BTKi -->
<div style="flex:1;min-width:200px;max-width:260px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 10px;margin-bottom:4px">AFTER BTKi</div>
<div style="width:3px;height:12px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--sage)"></div>
<div style="background:#e8f7f5;border:2px solid var(--sage);border-radius:12px;padding:14px 12px;text-align:center;font-size:.82rem;font-weight:600;color:var(--ink-deep);width:100%;margin-top:4px">
<div style="font-weight:700;color:var(--sage);margin-bottom:4px">Switch to Venetoclax-based</div>
<div style="font-size:.72rem;font-weight:400;color:var(--ink-body)">Venetoclax + Rituximab (fixed duration)</div>
</div>
</div>

<!-- After BCL2i -->
<div style="flex:1;min-width:200px;max-width:260px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 10px;margin-bottom:4px">AFTER BCL2i</div>
<div style="width:3px;height:12px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--sage)"></div>
<div style="background:#e8f7f5;border:2px solid var(--sage);border-radius:12px;padding:14px 12px;text-align:center;font-size:.82rem;font-weight:600;color:var(--ink-deep);width:100%;margin-top:4px">
<div style="font-weight:700;color:var(--sage);margin-bottom:4px">Switch to BTKi-based</div>
<div style="font-size:.72rem;font-weight:400;color:var(--ink-body)">Zanubrutinib / Acalabrutinib continuous</div>
</div>
</div>

<!-- Multi-refractory -->
<div style="flex:1;min-width:200px;max-width:260px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.68rem;font-weight:700;background:var(--cranberry);color:#fff;border-radius:999px;padding:2px 10px;margin-bottom:4px">MULTI-REFRACTORY</div>
<div style="width:3px;height:12px;background:var(--cranberry)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--cranberry)"></div>
<div style="background:#fce8ea;border:2.5px solid var(--cranberry);border-radius:12px;padding:14px 12px;text-align:center;font-size:.82rem;font-weight:600;color:var(--ink-deep);width:100%;margin-top:4px">
<div style="font-weight:700;color:var(--cranberry);margin-bottom:4px">Allo-HSCT / CAR-T</div>
<div style="font-size:.72rem;font-weight:400;color:var(--ink-body)">Clinical trial evaluation<br>Pirtobrutinib (non-covalent BTKi)</div>
</div>
</div>
</div>

</div>
</div>
<!-- END ALGORITHM 2 -->
<details>
<summary>Key Drug Profiles</summary>
<div class="table-wrap">
<table>
<thead><tr><th>Agent</th><th>Class</th><th>Key Points</th></tr></thead>
<tbody>
<tr><td>Ibrutinib</td><td>BTKi (1st gen)</td><td>Continuous therapy; AF, hypertension, bleeding risk</td></tr>
<tr><td>Acalabrutinib/Zanubrutinib</td><td>BTKi (2nd gen)</td><td>More selective; lower cardiac toxicity</td></tr>
<tr><td>Venetoclax</td><td>BCL2i</td><td>Fixed-duration with anti-CD20; TLS risk &rarr; dose ramp-up required</td></tr>
<tr><td>FCR</td><td>CIT</td><td>Selected fit young patients with mutated IGHV, no TP53; curative potential in subset</td></tr>
</tbody>
</table>
</div>
</details>
<div class="callout pitfall"><div class="callout-label">Pitfall</div><div class="callout-text">Do NOT confuse BTKi redistribution lymphocytosis with disease progression. Rising lymphocyte count with improving nodes/symptoms is an expected pharmacological effect.</div></div>
</section>

<!-- MODULE 6: COMPLICATIONS -->
<section class="module" id="mod-comp">
<div class="module-head"><h3>Module 6: Complications & Supportive Care</h3><span class="module-tag tag-comp">Complications</span></div>
<div class="module-grid">
<div class="card">
<h4>Autoimmune Cytopenias</h4>
<ul>
<li><strong>AIHA:</strong> ~10% of CLL patients; elevated LDH, low haptoglobin, positive DAT (IgG/C3)</li>
<li><strong>ITP:</strong> 5&ndash;7%; isolated thrombocytopenia with preserved marrow megakaryocytes</li>
<li><strong>Evans syndrome:</strong> concurrent AIHA + ITP</li>
<li><strong>PRCA:</strong> &lt;1%; low reticulocytes, arrested red cell precursors</li>
<li>Treatment: corticosteroids first &rarr; rituximab &rarr; alternative immunosuppression &rarr; anti-CLL therapy if refractory</li>
</ul>
</div>
<div class="card">
<h4>Infection Risk & Vaccination</h4>
<ul>
<li>Infections are the commonest cause of death (40&ndash;60%)</li>
<li>Multifactorial: low IgG, impaired antigen presentation, treatment toxicity</li>
<li>IgG replacement for profound hypogammaglobulinaemia + recurrent infections</li>
<li>Screen ALL patients for hepatitis B before anti-CD20 therapy</li>
<li>Vaccination: inactivated influenza, pneumococcal, herpes zoster &mdash; response is suboptimal but still recommended</li>
</ul>
</div>
<div class="card deep">
<h4>Richter Transformation</h4>
<ul>
<li>Occurs in ~5% of patients; transformation to DLBCL (most common) or Hodgkin lymphoma</li>
<li><strong>Clonally related (80%):</strong> poor prognosis, median survival &lt;1 year; consider allo-HSCT</li>
<li><strong>Clonally unrelated (20%):</strong> prognosis like de novo DLBCL; treat with R-CHOP</li>
<li>Associated with: unmutated IGHV, NOTCH1, TP53, CDKN2A/B, MYC mutations</li>
<li>PET/CT helps target biopsy to metabolically active sites</li>
</ul>
</div>
<div class="card">
<h4>Second Neoplasias</h4>
<ul>
<li>10&ndash;15% of CLL patients develop other cancers</li>
<li>Melanoma, lung carcinoma, lymphoma, GI tumours most frequent</li>
<li>Substantially increased risk of Merkel cell carcinoma</li>
<li>Secondary MDS/AML in ~5% of heavily pre-treated patients (e.g., post-FCR)</li>
</ul>
</div>
</div>
<!-- ALGORITHM 3: RICHTER TRANSFORMATION WORKUP -->
<div style="margin-top:24px;padding:28px;border-radius:20px;background:linear-gradient(135deg,#f7f4ef 0%,#fdf0f1 50%,#f7f4ef 100%);border:2px solid var(--border);position:relative">
<div style="display:flex;align-items:center;gap:12px;margin-bottom:24px">
<div style="width:44px;height:44px;border-radius:50%;background:var(--cranberry);display:flex;align-items:center;justify-content:center">
<span style="color:#fff;font-size:1.3rem;font-weight:700">3</span>
</div>
<div>
<h4 style="font-size:1.25rem;margin:0;color:var(--ink-deep);font-family:'Fraunces',serif">Richter Transformation Workup Algorithm</h4>
<span style="font-size:.78rem;color:var(--ink-body);opacity:.7">BloodðŸ©¸Doctor &middot; Dr Abdul Mannan FRCPath FCPS</span>
</div>
</div>
<div style="display:flex;flex-direction:column;align-items:center;gap:0">
<div style="background:#fce8ea;border:2.5px solid var(--cranberry);border-radius:14px;padding:16px 24px;text-align:center;font-size:.92rem;font-weight:700;color:var(--cranberry);max-width:460px;width:100%;box-shadow:0 4px 12px rgba(178,58,72,.15)">
&#9888; Clinical Suspicion: Rapid node growth + Rising LDH + B symptoms
</div>
<div style="display:flex;flex-direction:column;align-items:center"><div style="width:3px;height:28px;background:var(--cranberry)"></div><div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--cranberry)"></div></div>
<div style="background:var(--surface);border:2px solid var(--teal);border-radius:14px;padding:16px 24px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:420px;width:100%;box-shadow:0 4px 12px rgba(0,109,119,.1)">
PET/CT Scan<br><span style="font-weight:400;font-size:.8rem;color:var(--ink-body)">Identify most metabolically active site (SUV<sub>max</sub> often &gt;5)</span>
</div>
<div style="display:flex;flex-direction:column;align-items:center"><div style="width:3px;height:28px;background:var(--teal)"></div><div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--teal)"></div></div>
<div style="background:var(--surface);border:2px solid var(--teal);border-radius:14px;padding:16px 24px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:420px;width:100%;box-shadow:0 4px 12px rgba(0,109,119,.1)">
PET-Guided Tissue Biopsy<br><span style="font-weight:400;font-size:.8rem;color:var(--ink-body)">Core/excisional biopsy from hottest node</span>
</div>
<div style="display:flex;flex-direction:column;align-items:center"><div style="width:3px;height:28px;background:var(--teal)"></div><div style="width:0;height:0;border-left:8px solid transparent;border-right:8px solid transparent;border-top:10px solid var(--teal)"></div></div>
<!-- DECISION: Clonal relationship -->
<div style="background:#fff5e6;border:2.5px solid var(--amber);padding:18px 22px;text-align:center;font-size:.9rem;font-weight:600;color:var(--ink-deep);max-width:380px;width:100%;clip-path:polygon(50% 0%,100% 50%,50% 100%,0% 50%);min-height:120px;display:flex;align-items:center;justify-content:center;box-shadow:0 4px 16px rgba(224,159,62,.15)">
<span style="max-width:220px;display:block;line-height:1.4">Clonally related to CLL?</span>
</div>
<!-- Branches -->
<div style="display:flex;width:100%;max-width:700px;justify-content:center;gap:20px;margin-top:4px;flex-wrap:wrap">
<div style="flex:1;min-width:260px;max-width:320px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.7rem;font-weight:700;background:var(--cranberry);color:#fff;border-radius:999px;padding:2px 10px;margin-bottom:4px">YES (~80%)</div>
<div style="width:3px;height:14px;background:var(--cranberry)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--cranberry)"></div>
<div style="background:#fce8ea;border:2.5px solid var(--cranberry);border-radius:14px;padding:16px;text-align:center;font-weight:700;font-size:.9rem;color:var(--cranberry);width:100%;margin-top:4px">
Clonally Related DLBCL<div style="font-size:.78rem;font-weight:400;color:var(--ink-body);margin-top:6px">Poor prognosis (median OS &lt;1 year)<br>R-CHOP/R-EPOCH &rarr; allo-HSCT if eligible<br>Consider clinical trials, checkpoint inhibitors</div>
</div>
</div>
<div style="flex:1;min-width:260px;max-width:320px;display:flex;flex-direction:column;align-items:center">
<div style="font-size:.7rem;font-weight:700;background:var(--sage);color:#fff;border-radius:999px;padding:2px 10px;margin-bottom:4px">NO (~20%)</div>
<div style="width:3px;height:14px;background:var(--sage)"></div>
<div style="width:0;height:0;border-left:6px solid transparent;border-right:6px solid transparent;border-top:8px solid var(--sage)"></div>
<div style="background:#e8f7f5;border:2.5px solid var(--sage);border-radius:14px;padding:16px;text-align:center;font-weight:700;font-size:.9rem;color:var(--sage);width:100%;margin-top:4px">
Clonally Unrelated DLBCL<div style="font-size:.78rem;font-weight:400;color:var(--ink-body);margin-top:6px">Prognosis like de novo DLBCL<br>Standard R-CHOP (&plusmn; HSCT)<br>Much better outcomes</div>
</div>
</div>
</div>
</div>
</div>
<!-- END ALGORITHM 3 -->

<div class="callout red-flag"><div class="callout-label">Red Flag</div><div class="callout-text">Rapid node growth + rising LDH + B symptoms &rarr; suspect Richter transformation. Urgent tissue biopsy from the most metabolically active site (PET-guided) is essential.</div></div>
</section>

<!-- MODULE 7: OTHER DISORDERS -->
<section class="module" id="mod-other">
<div class="module-head"><h3>Module 7: Other Chronic B-cell Disorders</h3><span class="module-tag tag-diff">Differential</span></div>
<div class="module-grid">
<div class="card deep">
<h4>SMZL &mdash; Splenic Marginal Zone Lymphoma</h4>
<ul>
<li>Villous lymphocytes on blood film</li>
<li>Splenomegaly (often massive)</li>
<li>Intrasinusoidal marrow infiltration pattern</li>
<li>CD11c+, CD103&minus;, CD5&minus;, CD23&minus;</li>
<li>NOTCH2 mutations; no BRAF V600E</li>
<li>Treatment: rituximab-based; splenectomy in selected cases</li>
</ul>
</div>
<div class="card deep">
<h4>HCL &mdash; Hairy-Cell Leukaemia</h4>
<ul>
<li>Pancytopenia with monocytopenia (hallmark)</li>
<li>Hairy projections on lymphocytes</li>
<li>CD103+, CD123+, CD25+, CD11c+, Annexin A1+</li>
<li><strong>BRAF V600E</strong> in virtually all cases</li>
<li>Bone marrow: clear-zone infiltration, often dry tap</li>
<li>Treatment: purine analogues (cladribine/pentostatin) &rarr; high durable remissions</li>
<li>Relapsed: vemurafenib + rituximab</li>
</ul>
</div>
<div class="card deep">
<h4>Non-nodal Leukaemic MCL</h4>
<ul>
<li><strong>Cyclin D1+, t(11;14)(q13;q32)</strong> &mdash; key discriminator from CLL</li>
<li>SOX11&minus;, CD200+ (unlike nodal MCL)</li>
<li>Can mimic CLL morphologically</li>
<li>Generally more indolent than nodal MCL but requires different management</li>
</ul>
</div>
<div class="card deep">
<h4>Splenic B-cell Lymphoma with Prominent Nucleoli (HCL Variant)</h4>
<ul>
<li>CD25&minus;, no BRAF V600E (key differences from classical HCL)</li>
<li>CD123+, Annexin A1&minus;</li>
<li>MAP2K1 mutations common</li>
<li>Does NOT respond well to purine analogues alone</li>
<li>Splenectomy may be considered</li>
</ul>
</div>
<div class="card">
<h4>SDRPL</h4>
<ul>
<li>Splenic diffuse red pulp small B-cell lymphoma</li>
<li>Rare; involves splenic red pulp diffusely</li>
<li>CD5&minus;, CD23&minus;, Annexin A1&minus;</li>
<li>CCND3 mutations described</li>
</ul>
</div>
<div class="card">
<h4>Follicular Lymphoma (Leukaemic Phase)</h4>
<ul>
<li>CD10+, BCL6+, t(14;18)(q32;q21)</li>
<li>Cleaved nuclei (centrocytes) on blood film</li>
<li>CD5&minus;, CD23&minus; or weak</li>
<li>Paratrabecular marrow infiltration (unlike CLL)</li>
</ul>
</div>
</div>
</section>

<!-- MODULE 8: FIGURES -->
<section class="module" id="mod-fig">
<div class="module-head"><h3>Module 8: Figures &amp; Visual Atlas</h3><span class="module-tag tag-fig">Visual Guide</span></div>
<div class="module-grid">
<div class="card"><h4>Fig 1 &mdash; CLL Pathogenesis</h4><img src="images/1.png" alt="Genetic and epigenetic events leading to CLL" style="width:100%;border-radius:10px;margin:8px 0"><p>CLL evolves stepwise from HSC genetic/epigenetic lesions through polyclonal B-cell expansion, oligoclonal selection, MBL, and finally overt CLL.</p></div>
<div class="card"><h4>Fig 2 &mdash; Blood Film: Typical CLL</h4><img src="images/2.png" alt="CLL blood film showing small mature lymphocytes and smudge cells" style="width:100%;border-radius:10px;margin:8px 0"><p>Small mature lymphocytes with scanty cytoplasm and smudge cells (Gumprecht cells).</p></div>
<div class="card"><h4>Fig 3 &mdash; Transforming CLL</h4><img src="images/3.png" alt="CLL with increased prolymphocytes" style="width:100%;border-radius:10px;margin:8px 0"><p>Increased prolymphocytes (&gt;15%) signals accelerated/transforming CLL. Dual population of small lymphocytes and larger nucleolated cells.</p></div>
<div class="card"><h4>Fig 4 &mdash; Polyclonal B-cell Lymphocytosis</h4><img src="images/4.png" alt="Binucleated lymphocytes in polyclonal B-cell lymphocytosis" style="width:100%;border-radius:10px;margin:8px 0"><p>Binucleated lymphocytes characteristic of persistent polyclonal B-cell lymphocytosis (a benign mimic).</p></div>
<div class="card"><h4>Fig 5 &mdash; Richter Syndrome</h4><img src="images/5.png" alt="Large blast cells of Richter transformation" style="width:100%;border-radius:10px;margin:8px 0"><p>Large blast-like atypical cells corresponding to Richter syndrome with blood involvement.</p></div>
<div class="card"><h4>Fig 6 &mdash; Treatment Algorithm</h4><img src="images/6.png" alt="CLL treatment algorithm flowchart" style="width:100%;border-radius:10px;margin:8px 0"><p>Treatment pathway integrates disease activity criteria, biology (IGHV/TP53), and patient fitness.</p></div>
<div class="card"><h4>Fig 6a &mdash; Rai/Binet Staging</h4><img src="images/6a.png" alt="Rai and Binet staging table" style="width:100%;border-radius:10px;margin:8px 0"><p>Clinical staging systems for CLL prognosis and treatment planning.</p></div>
<div class="card"><h4>Fig 7 &mdash; SMZL Blood Film</h4><img src="images/7.png" alt="Villous lymphocytes in SMZL" style="width:100%;border-radius:10px;margin:8px 0"><p>Villous lymphocytes supporting SMZL pattern on blood film.</p></div>
<div class="card"><h4>Fig 8 &mdash; Hairy Cell Leukaemia</h4><img src="images/8.png" alt="Hairy cells with fine cytoplasmic projections" style="width:100%;border-radius:10px;margin:8px 0"><p>Typical hairy cells with fine cytoplasmic projections supporting HCL diagnosis.</p></div>
<div class="card"><h4>Fig 9 &mdash; BM Trephine in HCL</h4><img src="images/9.png" alt="Bone marrow trephine showing HCL infiltration" style="width:100%;border-radius:10px;margin:8px 0"><p>Marrow trephine showing classic clear-zone (fried egg) infiltration pattern.</p></div>
<div class="card"><h4>Fig 10 &mdash; BM Trephine HCL (Paraffin)</h4><img src="images/10.png" alt="BM trephine HCL paraffin section" style="width:100%;border-radius:10px;margin:8px 0"><p>Paraffin section reinforcing HCL diagnosis with diffuse marrow involvement.</p></div>
<div class="card"><h4>Fig 11 &mdash; Mantle Cell Lymphoma</h4><img src="images/11.png" alt="Leukaemic MCL cells on blood film" style="width:100%;border-radius:10px;margin:8px 0"><p>Leukaemic MCL cells can mimic CLL morphologically but differ biologically (Cyclin D1+, t(11;14)).</p></div>
<div class="card"><h4>Fig 12 &mdash; Follicular Lymphoma</h4><img src="images/12.png" alt="Follicular lymphoma leukaemic phase blood film" style="width:100%;border-radius:10px;margin:8px 0"><p>Cleaved nuclei and centrocyte morphology supporting follicular lymphoma leukaemic spillover.</p></div>
<div class="card"><h4>Fig 13 &mdash; HCL Variant</h4><img src="images/13.png" alt="Splenic B-cell lymphoma with prominent nucleoli" style="width:100%;border-radius:10px;margin:8px 0"><p>Nucleolated villous cells suggesting splenic B-cell lymphoma/leukaemia with prominent nucleoli (HCL variant).</p></div>
</div>
</section>

<!-- QUIZ ZONE -->
<section class="quiz-zone" id="quiz-zone">
<div style="display:flex;justify-content:space-between;align-items:center;flex-wrap:wrap;gap:12px;margin-bottom:14px">
<h3 style="font-size:1.5rem">Quiz Zone</h3>
<div style="font-size:.82rem;color:var(--teal);font-weight:600">BloodðŸ©¸Doctor By Dr Abdul Mannan FRCPath FCPS</div>
</div>
<div class="quiz-tabs">
<button class="quiz-tab active" id="tabMCQ" onclick="switchTab('mcq')">MCQ (20)</button>
<button class="quiz-tab" id="tabEMQ" onclick="switchTab('emq')">EMQ (20)</button>
<button class="quiz-tab" id="tabVMCQ" onclick="switchTab('vmcq')">Vignette MCQ (15)</button>
<button class="quiz-tab" id="tabVEMQ" onclick="switchTab('vemq')">Vignette EMQ (10)</button>
</div>
<div class="quiz-progress"><div class="quiz-progress-bar" id="progressBar" style="width:0%"></div></div>
<div id="quizContainer"></div>
<div class="results-card" id="resultsCard">
<div class="results-score" id="resScore">0%</div>
<div class="results-award" id="resAward"></div>
<div class="results-grid">
<div class="results-stat"><div class="label">MCQ</div><div class="value" id="resMCQ">0%</div></div>
<div class="results-stat"><div class="label">EMQ</div><div class="value" id="resEMQ">0%</div></div>
<div class="results-stat"><div class="label">Vignette MCQ</div><div class="value" id="resVMCQ">0%</div></div>
<div class="results-stat"><div class="label">Vignette EMQ</div><div class="value" id="resVEMQ">0%</div></div>
<div class="results-stat"><div class="label">Overall</div><div class="value" id="resOverall">0%</div></div>
</div>
<div id="resGuidance" style="text-align:left;padding:14px;border-radius:12px;background:var(--bg-ivory);margin-top:14px;display:none"></div>
<div style="margin-top:18px;display:flex;gap:12px;justify-content:center">
<button class="cta-primary" onclick="resetQuiz()">Reset & Reshuffle</button>
<button class="cta-outline" onclick="showAllQuestions()">Review Answers</button>
</div>
</div>
<div style="margin-top:14px;display:flex;gap:12px;flex-wrap:wrap">
<button class="cta-primary" id="finishBtn" onclick="finishQuiz()" style="display:none">Finish & Score</button>
<button class="cta-outline" onclick="resetQuiz()">Reset</button>
</div>
</section>

<!-- BIBLIOGRAPHY -->
<section class="module" id="mod-bib">
<div class="module-head"><h3>Bibliography & Abbreviations</h3><span class="module-tag tag-dx">Reference</span></div>
<div class="card">
<h4>Core References</h4>
<ol style="font-size:.85rem;line-height:1.8;padding-left:18px">
<li>Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <em>Blood.</em> 2018;131:2745-2760.</li>
<li>Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guideline. <em>Ann Oncol.</em> 2021;32:23-33.</li>
<li>Eichhorst B, et al. ESMO update for CLL (2024). <em>Ann Oncol.</em> 2024.</li>
<li>Grever MR, Abdel-Wahab O, et al. Consensus guidelines for classic hairy cell leukemia. <em>Blood.</em> 2017;129:553-560.</li>
<li>Montserrat E. Chapter 23: CLL and other chronic B-cell lymphoproliferative disorders. In: <em>Hoffbrand's Postgraduate Haematology</em>, 8th ed. Wiley; 2025.</li>
</ol>
</div>
<details>
<summary>Abbreviations</summary>
<div class="table-wrap">
<table>
<tbody>
<tr><td><strong>AIHA</strong></td><td>Autoimmune haemolytic anaemia</td></tr>
<tr><td><strong>BCL2i</strong></td><td>BCL2 inhibitor (e.g., venetoclax)</td></tr>
<tr><td><strong>BCR</strong></td><td>B-cell receptor</td></tr>
<tr><td><strong>BTKi</strong></td><td>Bruton tyrosine kinase inhibitor</td></tr>
<tr><td><strong>CIT</strong></td><td>Chemoimmunotherapy</td></tr>
<tr><td><strong>CLL</strong></td><td>Chronic lymphocytic leukaemia</td></tr>
<tr><td><strong>DAT</strong></td><td>Direct antiglobulin test</td></tr>
<tr><td><strong>DLBCL</strong></td><td>Diffuse large B-cell lymphoma</td></tr>
<tr><td><strong>FCR</strong></td><td>Fludarabine, cyclophosphamide, rituximab</td></tr>
<tr><td><strong>FISH</strong></td><td>Fluorescence in situ hybridisation</td></tr>
<tr><td><strong>HCL</strong></td><td>Hairy-cell leukaemia</td></tr>
<tr><td><strong>IGHV</strong></td><td>Immunoglobulin heavy-chain variable region</td></tr>
<tr><td><strong>ITP</strong></td><td>Immune thrombocytopenia</td></tr>
<tr><td><strong>LDT</strong></td><td>Lymphocyte doubling time</td></tr>
<tr><td><strong>MBL</strong></td><td>Monoclonal B-cell lymphocytosis</td></tr>
<tr><td><strong>MCL</strong></td><td>Mantle cell lymphoma</td></tr>
<tr><td><strong>MRD</strong></td><td>Minimal residual disease</td></tr>
<tr><td><strong>PRCA</strong></td><td>Pure red-cell aplasia</td></tr>
<tr><td><strong>SLL</strong></td><td>Small lymphocytic lymphoma</td></tr>
<tr><td><strong>SMZL</strong></td><td>Splenic marginal zone lymphoma</td></tr>
<tr><td><strong>TP53</strong></td><td>Tumour protein p53</td></tr>
<tr><td><strong>uMRD</strong></td><td>Undetectable minimal residual disease</td></tr>
</tbody>
</table>
</div>
</details>
</section>

</main>

<!-- FOOTER -->
<footer class="footer">
<div><strong>BloodðŸ©¸Doctor</strong> By Dr Abdul Mannan FRCPath FCPS &middot; blooddoctor.co@gmail.com</div>
<div>Educational resource for trainees. Not a substitute for clinical judgement. Content derived from Hoffbrand's Postgraduate Haematology, 8th edition.</div>
</footer>
</div>

<script>
// === QUIZ BANK ===
const QUIZ_BANK={mcq:[{id:"m1",type:"mcq",stem:"A patient has persistent monoclonal B-lymphocytosis of 6 \u00d7 10\u2079/L for 4 months with typical CLL phenotype and no tissue biopsy. Most appropriate diagnosis?",options:["MBL","CLL","SLL","LPL"],correctIndex:1,rationale:"CLL requires \u22655 \u00d7 10\u2079/L clonal B cells in blood for \u22653 months with compatible phenotype.",topic:"Diagnosis",difficulty:"easy"},{id:"m2",type:"mcq",stem:"Which immunophenotype is most consistent with typical CLL?",options:["CD5\u2212, CD23\u2212, strong SmIg","CD5+, CD23+, CD200+, weak SmIg/CD20","CD10+, BCL6+, CD5\u2212","CD103+, CD123+, Annexin A1+"],correctIndex:1,rationale:"Typical CLL co-expresses CD5 and CD23 with weak surface immunoglobulin and CD20, often CD200+.",topic:"Immunophenotype",difficulty:"easy"},{id:"m3",type:"mcq",stem:"Which genetic profile most strongly predicts poor response to chemoimmunotherapy?",options:["Isolated del(13q)","Trisomy 12 alone","del(17p)/TP53 disruption","Mutated IGHV only"],correctIndex:2,rationale:"TP53 pathway disruption is the key marker of poor CIT response and guides pathway inhibitor use.",topic:"Predictive biomarkers",difficulty:"medium"},{id:"m4",type:"mcq",stem:"In CLL, unmutated IGHV status generally indicates:",options:["More indolent biology","Better CIT outcomes","More aggressive clinical behaviour","No prognostic relevance"],correctIndex:2,rationale:"IGHV-unmutated disease tends toward faster progression and historically inferior CIT outcomes.",topic:"Prognosis",difficulty:"easy"},{id:"m5",type:"mcq",stem:"Which feature alone is NOT a treatment-start criterion in otherwise stable CLL?",options:["Hb <110 g/L from marrow failure","Progressive symptomatic splenomegaly","High WBC count without other active-disease features","B symptoms"],correctIndex:2,rationale:"High leukocyte count by itself usually does not justify treatment initiation.",topic:"Treatment criteria",difficulty:"easy"},{id:"m6",type:"mcq",stem:"A CLL patient on BTKi develops transient rising lymphocyte count but improving nodes and symptoms. Best interpretation?",options:["Definite progression","Expected redistribution effect","Richter transformation","Autoimmune flare"],correctIndex:1,rationale:"BTKi can cause temporary blood lymphocytosis due to tissue redistribution.",topic:"Treatment monitoring",difficulty:"medium"},{id:"m7",type:"mcq",stem:"In suspected Richter transformation, the most urgent next step is:",options:["Increase steroid dose only","Start empiric chlorambucil","Tissue biopsy from metabolically active site","Repeat CBC in 3 months"],correctIndex:2,rationale:"Transformation requires histologic confirmation; PET/CT helps identify the best biopsy site.",topic:"Complications",difficulty:"medium"},{id:"m8",type:"mcq",stem:"AIHA in CLL is most likely when anaemia is accompanied by:",options:["Low LDH and high haptoglobin","Elevated LDH and positive DAT","Normal smear and DAT negative","Isolated neutropenia only"],correctIndex:1,rationale:"A haemolytic profile with DAT positivity strongly supports AIHA.",topic:"Autoimmune cytopenias",difficulty:"easy"},{id:"m9",type:"mcq",stem:"Which first-line approach is standard for most asymptomatic early CLL?",options:["Immediate CIT","Immediate BTKi for all","Active surveillance","Splenectomy"],correctIndex:2,rationale:"Early asymptomatic disease is managed with watchful waiting.",topic:"Treatment strategy",difficulty:"easy"},{id:"m10",type:"mcq",stem:"A major toxicity profile classically associated with ibrutinib includes:",options:["Severe neuropathy only","Atrial fibrillation, hypertension, bleeding","Hyperpigmentation only","Isolated nephrotoxicity only"],correctIndex:1,rationale:"Cardiovascular and bleeding toxicities are key class effects.",topic:"Targeted therapy",difficulty:"easy"},{id:"m11",type:"mcq",stem:"Why is venetoclax dose ramp-up required?",options:["To prevent cytokine storm","To prevent tumour lysis syndrome","To reduce neuropathy","To improve oral absorption only"],correctIndex:1,rationale:"Gradual escalation reduces tumour lysis risk.",topic:"Targeted therapy",difficulty:"easy"},{id:"m12",type:"mcq",stem:"Which statement best fits isolated del(13q) in CLL?",options:["Universally refractory disease","Generally favourable prognostic pattern","Indicates Hodgkin transformation","Contraindicates all targeted agents"],correctIndex:1,rationale:"Isolated del(13q) is usually linked with more favourable biology.",topic:"Prognosis",difficulty:"easy"},{id:"m13",type:"mcq",stem:"Which marker combination most supports classical HCL?",options:["CD5+, CD23+, Cyclin D1+","CD11c+, CD25+, CD103+, CD123+, BRAF V600E","CD10+, BCL6+, t(14;18)","CD5+, CD23\u2212, SOX11+"],correctIndex:1,rationale:"Classical HCL has a characteristic marker profile and near-universal BRAF V600E.",topic:"HCL",difficulty:"medium"},{id:"m14",type:"mcq",stem:"Standard front-line therapy for most active classical HCL cases is:",options:["Chlorambucil monotherapy","Purine analogue (cladribine or pentostatin)","Splenectomy first in all","Immediate allo-HSCT"],correctIndex:1,rationale:"Purine analogues provide high and durable responses.",topic:"HCL treatment",difficulty:"easy"},{id:"m15",type:"mcq",stem:"Which feature favours splenic B-cell lymphoma/leukaemia with prominent nucleoli over classical HCL?",options:["Universal BRAF V600E","CD25 negativity and no BRAF V600E","Frequent monocytopenia","Dry tap in almost all cases"],correctIndex:1,rationale:"The variant form typically lacks CD25 and BRAF V600E.",topic:"HCL variant",difficulty:"medium"},{id:"m16",type:"mcq",stem:"In SMZL, which pattern is most characteristic?",options:["CD103 and CD123 co-expression in all cases","Intrasinusoidal marrow infiltration with villous lymphocytes","Cyclin D1 overexpression from t(11;14)","No splenic involvement"],correctIndex:1,rationale:"SMZL often shows villous lymphocytes and intrasinusoidal marrow involvement.",topic:"SMZL",difficulty:"medium"},{id:"m17",type:"mcq",stem:"Which finding helps distinguish non-nodal leukaemic MCL from typical CLL?",options:["Consistent CD23 bright positivity","Cyclin D1 expression and t(11;14)","Frequent smudge cells only","Universal CD200 positivity"],correctIndex:1,rationale:"Cyclin D1 and t(11;14) are central discriminatory markers for MCL.",topic:"MCL differential",difficulty:"medium"},{id:"m18",type:"mcq",stem:"Which statement about MBL is most accurate?",options:["Always requires immediate therapy","Defined by \u22655 \u00d7 10\u2079/L clonal B cells","Usually monitored; progression risk exists but is limited","Equivalent to aggressive lymphoma"],correctIndex:2,rationale:"MBL is a precursor state; monitoring is standard unless progression occurs.",topic:"MBL",difficulty:"easy"},{id:"m19",type:"mcq",stem:"A CLL patient with refractory autoimmune cytopenia despite standard immune therapy should next be considered for:",options:["Observation only","Anti-CLL directed therapy","Antibiotics alone","Immediate splenectomy in all cases"],correctIndex:1,rationale:"Refractory autoimmune cytopenia is an accepted trigger for anti-CLL therapy.",topic:"Autoimmune cytopenias",difficulty:"medium"},{id:"m20",type:"mcq",stem:"Which is true about response categories in CLL trials?",options:["MRD status has no clinical value","CR with undetectable MRD tends to have better outcomes","PR requires normal marrow biopsy","Stable disease means all symptoms resolved"],correctIndex:1,rationale:"uMRD CR generally correlates with deeper response quality and better outcomes.",topic:"Response assessment",difficulty:"medium"}],emq:[{id:"e1",type:"emq",stem:"Clonal B cells 3 \u00d7 10\u2079/L, no adenopathy, no organomegaly, no symptoms.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:2,rationale:"Below 5 \u00d7 10\u2079/L clonal B cells without disease features supports MBL.",topic:"Diagnostic classification",difficulty:"easy"},{id:"e2",type:"emq",stem:"Typical CLL phenotype with clonal B cells 8 \u00d7 10\u2079/L for 4 months.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:0,rationale:"Meets blood count and duration threshold for CLL.",topic:"Diagnostic classification",difficulty:"easy"},{id:"e3",type:"emq",stem:"Tissue-dominant disease with CLL phenotype but blood clonal B cells <5 \u00d7 10\u2079/L.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:1,rationale:"SLL represents tissue-dominant disease within the same biologic spectrum.",topic:"Diagnostic classification",difficulty:"medium"},{id:"e4",type:"emq",stem:"Villous lymphocytes, splenomegaly, intrasinusoidal marrow pattern, CD11c+, CD103\u2212.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:3,rationale:"This profile is classic for SMZL.",topic:"Diagnostic classification",difficulty:"medium"},{id:"e5",type:"emq",stem:"Cyclin D1 positivity with t(11;14) in a leukaemic presentation.",options:["CLL","SLL","MBL","SMZL","Classical HCL","Non-nodal leukaemic MCL","LPL/WM","Splenic B-cell lymphoma/leukaemia with prominent nucleoli","Follicular lymphoma (leukaemic phase)","SDRPL"],correctIndex:5,rationale:"t(11;14) with cyclin D1 is strongly supportive of MCL.",topic:"Diagnostic classification",difficulty:"medium"},{id:"e6",type:"emq",stem:"Biomarker most linked with CIT resistance and pathway-inhibitor preference.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:1,rationale:"TP53 disruption drives major resistance to CIT.",topic:"Predictive markers",difficulty:"easy"},{id:"e7",type:"emq",stem:"Pattern more often associated with indolent biology and longer treatment-free interval.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:3,rationale:"Mutated IGHV generally indicates slower disease behaviour.",topic:"Prognosis",difficulty:"easy"},{id:"e8",type:"emq",stem:"Marker associated with aggressive disease kinetics and quicker need for treatment.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:6,rationale:"Short LDT indicates rapid clonal expansion.",topic:"Prognosis",difficulty:"medium"},{id:"e9",type:"emq",stem:"Mutation linked to clinical resistance during BTKi therapy.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:8,rationale:"BTK pathway mutations are a known mechanism of BTKi resistance.",topic:"Relapse biology",difficulty:"hard"},{id:"e10",type:"emq",stem:"Mutation pattern associated with resistance during venetoclax therapy.",options:["Isolated del(13q)","del(17p)/TP53 disruption","Unmutated IGHV","Mutated IGHV","Complex karyotype","High beta-2 microglobulin","Short lymphocyte doubling time","NOTCH1 mutation","BTK mutation","BCL2 resistance mutation"],correctIndex:9,rationale:"Acquired BCL2 resistance mutations can drive venetoclax failure.",topic:"Relapse biology",difficulty:"hard"},{id:"e11",type:"emq",stem:"Sudden anaemia, high LDH, low haptoglobin, DAT positive.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:0,rationale:"This haemolytic pattern supports AIHA.",topic:"Complications",difficulty:"easy"},{id:"e12",type:"emq",stem:"CLL with severe isolated thrombocytopenia, marrow megakaryocytes preserved.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:1,rationale:"Pattern is consistent with immune thrombocytopenia.",topic:"Complications",difficulty:"medium"},{id:"e13",type:"emq",stem:"AIHA plus immune thrombocytopenia occurring together.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:7,rationale:"Combined AIHA and ITP defines Evans syndrome.",topic:"Complications",difficulty:"easy"},{id:"e14",type:"emq",stem:"Rapid clinical deterioration, rising LDH, aggressive DLBCL clone with poor prognosis.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:3,rationale:"Clonally related Richter transformation is typically high risk.",topic:"Complications",difficulty:"hard"},{id:"e15",type:"emq",stem:"Rising lymphocyte count soon after BTKi initiation despite improving nodes.",options:["AIHA","ITP","PRCA","Richter transformation (clonally related)","Richter transformation (clonally unrelated)","BTKi redistribution lymphocytosis","Hypogammaglobulinaemia-related infection risk","Evans syndrome","Cold agglutinin disease","Treatment-related marrow toxicity"],correctIndex:5,rationale:"This is expected redistribution, not immediate progression.",topic:"Treatment monitoring",difficulty:"medium"},{id:"e16",type:"emq",stem:"Newly diagnosed asymptomatic early CLL without active disease criteria.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:0,rationale:"Observation is standard when no treatment trigger is present.",topic:"Treatment selection",difficulty:"easy"},{id:"e17",type:"emq",stem:"Fit younger patient with favourable biology where CIT is still selectively considered.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:3,rationale:"FCR may remain an option in selected younger fit patients.",topic:"Treatment selection",difficulty:"medium"},{id:"e18",type:"emq",stem:"CLL relapse after one pathway-inhibitor class with renewed treatment indication.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:2,rationale:"Class-switch strategy is core in relapsed disease management.",topic:"Relapsed CLL",difficulty:"hard"},{id:"e19",type:"emq",stem:"Classical HCL with treatment indication and no major contraindication.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:6,rationale:"Purine analogues are standard front-line for active classical HCL.",topic:"HCL treatment",difficulty:"easy"},{id:"e20",type:"emq",stem:"Suspected Richter transformation based on abrupt clinical shift and high LDH.",options:["Active surveillance","BTKi-based therapy","Venetoclax + anti-CD20","FCR in selected fit younger patient","Chlorambucil palliation (very frail)","Allo-HSCT evaluation","Cladribine/pentostatin","BRAF inhibitor (relapsed HCL)","Rituximab for SMZL","Urgent tissue biopsy"],correctIndex:9,rationale:"Histologic confirmation by tissue biopsy is essential.",topic:"Complications",difficulty:"medium"}],
vmcq:[
{id:"cv1",type:"mcq",stem:"A 72-year-old man presents with fatigue and recurrent sinopulmonary infections over 6 months. FBC: WBC 68 \u00d7 10\u2079/L (lymphocytes 62 \u00d7 10\u2079/L), Hb 128 g/L, platelets 185 \u00d7 10\u2079/L. Blood film: small mature lymphocytes, smudge cells. Flow cytometry: CD5+, CD19+, CD23+, CD200+, weak SmIg, FMC7\u2212. FISH: isolated del(13q14). IGHV mutated. Serum IgG 3.2 g/L (normal 6\u201316). No palpable lymphadenopathy. What is the most appropriate next management step?",options:["Start ibrutinib","Start FCR","Active surveillance with IgG monitoring","Immediate venetoclax + obinutuzumab"],correctIndex:2,rationale:"This is Rai stage 0 with mutated IGHV and favourable del(13q). Despite hypogammaglobulinaemia, treatment is only for active/progressive disease. IgG replacement may be considered if recurrent infections worsen, but CLL-directed therapy is not yet indicated.",topic:"Treatment criteria",difficulty:"hard"},
{id:"cv2",type:"mcq",stem:"A 58-year-old woman with CLL (unmutated IGHV, no TP53 abnormality) started ibrutinib 6 weeks ago for progressive bulky lymphadenopathy. At follow-up, lymph nodes decreased by 40%, spleen non-palpable, but absolute lymphocyte count has risen from 45 to 112 \u00d7 10\u2079/L. She feels well with no B symptoms. What is the most appropriate interpretation?",options:["Treatment failure requiring immediate switch to venetoclax","Richter transformation","Expected pharmacological redistribution lymphocytosis","Laboratory error requiring repeat testing"],correctIndex:2,rationale:"BTK inhibitors mobilise CLL cells from tissue compartments into blood, causing transient lymphocytosis that can persist for months. This is NOT progression \u2014 clinical response is defined by nodal/splenic reduction, not blood counts.",topic:"Treatment monitoring",difficulty:"hard"},
{id:"cv3",type:"mcq",stem:"A 65-year-old man with CLL (Binet B, unmutated IGHV, 8 years) presents with sudden worsening fatigue, drenching night sweats, 8 kg weight loss in 4 weeks, and rapidly enlarging right cervical node now 7 cm. LDH risen from 210 to 890 U/L. Beta-2 microglobulin 8.4 mg/L. What is the single most important next investigation?",options:["Repeat FISH panel for del(17p)","PET/CT with guided tissue biopsy of the most active node","CT chest/abdomen with 3-month follow-up","Bone marrow aspirate and trephine only"],correctIndex:1,rationale:"The clinical picture strongly suggests Richter transformation: abrupt B symptoms, rapidly enlarging single mass, markedly elevated LDH. PET/CT identifies the most metabolically active site (SUVmax often >5) to guide biopsy for histological confirmation.",topic:"Richter transformation",difficulty:"hard"},
{id:"cv4",type:"mcq",stem:"A 74-year-old woman with CLL (Rai II) develops progressive anaemia. Hb 78 g/L, reticulocytes 8.2%, LDH 620 U/L, haptoglobin undetectable, bilirubin 42 \u03bcmol/L (unconjugated predominant), DAT strongly positive (IgG + C3d). Platelets 155 \u00d7 10\u2079/L. Film shows spherocytes and polychromasia. What is the most likely diagnosis?",options:["Marrow infiltration by CLL","Pure red cell aplasia","Autoimmune haemolytic anaemia","Microangiopathic haemolytic anaemia"],correctIndex:2,rationale:"Reticulocytosis, elevated LDH, absent haptoglobin, unconjugated hyperbilirubinaemia, positive DAT (IgG+C3d), and spherocytes is diagnostic of warm AIHA (~10% of CLL). PRCA shows low reticulocytes. Marrow infiltration causes hypoproliferative anaemia. MAHA shows schistocytes.",topic:"Autoimmune complications",difficulty:"hard"},
{id:"cv5",type:"mcq",stem:"A 62-year-old man diagnosed with CLL: WBC 28 \u00d7 10\u2079/L, Hb 142 g/L, platelets 220 \u00d7 10\u2079/L. CLL score 5/5. FISH: del(17p13.1) in 35% of nuclei. TP53 mutation confirmed by NGS. IGHV unmutated. No lymphadenopathy or organomegaly, asymptomatic. What is the most appropriate management?",options:["Immediate ibrutinib","Immediate venetoclax + obinutuzumab","Active surveillance with close monitoring","FCR given his fitness"],correctIndex:2,rationale:"Despite high-risk biology (del(17p)/TP53, unmutated IGHV), treatment is ONLY initiated when active disease criteria are met. This is Rai 0 with no symptoms, cytopenias, or organomegaly. Close monitoring essential given high-risk genetics, but early treatment has not shown benefit. FCR contraindicated with TP53.",topic:"Treatment criteria",difficulty:"hard"},
{id:"cv6",type:"mcq",stem:"A 55-year-old woman with CLL (mutated IGHV, normal FISH, Binet C with Hb 92 g/L from marrow failure) is being considered for first-line therapy. Fit, ECOG 0, no significant comorbidities, CrCl 95 mL/min. Which treatment option may still be considered in this specific subgroup?",options:["Chlorambucil monotherapy","Bendamustine-rituximab only","FCR (fludarabine, cyclophosphamide, rituximab)","Splenectomy as first-line"],correctIndex:2,rationale:"In fit, young patients with mutated IGHV and no TP53 disruption, FCR remains a legitimate option with potential for long-term remission (60%+ of mutated IGHV patients achieve >10 year remissions). While BTKi/BCL2i are increasingly preferred, FCR is still selectively considered in this favourable subgroup.",topic:"First-line therapy",difficulty:"hard"},
{id:"cv7",type:"mcq",stem:"A 68-year-old man with CLL (unmutated IGHV) on ibrutinib for 3 years with good response now presents with progressive lymphadenopathy and rising LDH despite continued therapy. Marrow confirms CLL (no transformation). Sequencing reveals BTK C481S mutation. What is the most appropriate next step?",options:["Increase ibrutinib dose to 560 mg twice daily","Switch to venetoclax-based therapy","Add rituximab to ibrutinib","Proceed directly to allo-HSCT"],correctIndex:1,rationale:"BTK C481S is the commonest acquired resistance mechanism to covalent BTKi, disrupting the covalent binding site. Standard approach is class-switch to venetoclax \u00b1 anti-CD20. Dose escalation will not overcome the resistance mutation.",topic:"Relapse management",difficulty:"hard"},
{id:"cv8",type:"mcq",stem:"A 70-year-old woman presents with pancytopenia: WBC 2.8 \u00d7 10\u2079/L (monocytes 0.1 \u00d7 10\u2079/L \u2014 markedly reduced), Hb 98 g/L, platelets 72 \u00d7 10\u2079/L. Film: lymphoid cells with pale grey cytoplasm and fine hair-like projections. BM aspirate: dry tap. Flow: CD19+, CD11c+, CD25+, CD103+, CD123+, Annexin A1+, CD5\u2212, CD23\u2212. BRAF V600E confirmed. First-line treatment?",options:["Rituximab monotherapy","Cladribine","Ibrutinib","Splenectomy"],correctIndex:1,rationale:"This is classical HCL (pancytopenia with monocytopenia, hairy cells, dry tap, Annexin A1+, BRAF V600E). First-line: purine analogue (cladribine or pentostatin), achieving durable CR in >80%. Splenectomy is historical.",topic:"HCL treatment",difficulty:"hard"},
{id:"cv9",type:"mcq",stem:"A 75-year-old woman presents with massive splenomegaly (14 cm below costal margin), WBC 18 \u00d7 10\u2079/L with circulating lymphoid cells showing short villous projections. Flow: CD19+, CD11c+, CD5\u2212, CD23\u2212, CD103\u2212, CD25\u2212, BRAF V600E negative. NOTCH2 mutation detected. BM biopsy: intrasinusoidal infiltration. Diagnosis?",options:["Classical HCL","Splenic marginal zone lymphoma","CLL","Follicular lymphoma"],correctIndex:1,rationale:"Villous lymphocytes + massive splenomegaly + intrasinusoidal marrow + CD103\u2212/CD25\u2212/BRAF\u2212 + NOTCH2 mutation is classic SMZL. Classical HCL would have CD103+/CD25+/BRAF+. CLL would be CD5+/CD23+.",topic:"Differential diagnosis",difficulty:"hard"},
{id:"cv10",type:"mcq",stem:"A 60-year-old man with CLL (Binet A, 2 years) has routine bloods: WBC 32 \u00d7 10\u2079/L, Hb 138 g/L, platelets 195 \u00d7 10\u2079/L. WBC was 18 \u00d7 10\u2079/L 12 months ago and 24 \u00d7 10\u2079/L 6 months ago. No symptoms, no palpable lymphadenopathy, no organomegaly. What is the LDT and does this patient need treatment?",options:["LDT ~12 months \u2014 meets treatment criteria","LDT ~12 months \u2014 borderline, continue close monitoring","LDT ~6 months \u2014 meets treatment criteria","LDT ~24 months \u2014 active surveillance"],correctIndex:1,rationale:"LDT is approximately 12 months (18\u219232 over 12 months). iwCLL guidelines specify LDT <6 months as treatment trigger, or >50% rise in 2 months. LDT of 12 months is borderline \u2014 warrants closer monitoring but does not mandate treatment alone.",topic:"Prognosis and monitoring",difficulty:"hard"},
{id:"cv11",type:"mcq",stem:"A 64-year-old man starting venetoclax for relapsed CLL. WBC 120 \u00d7 10\u2079/L with bulky 8 cm abdominal lymphadenopathy. Creatinine 98 \u03bcmol/L, urate 480 \u03bcmol/L, potassium 4.8 mmol/L. What is the most critical safety measure?",options:["Immediate full-dose venetoclax 400 mg daily","5-week dose ramp-up with TLS prophylaxis, hydration, and monitoring","Loading dose of 800 mg for 3 days then maintenance","Start with rituximab alone for 2 cycles first"],correctIndex:1,rationale:"Venetoclax causes rapid apoptosis creating high TLS risk with high tumour burden. Mandatory: 5-week ramp-up (20\u219250\u2192100\u2192200\u2192400 mg), aggressive hydration, allopurinol/rasburicase, serial TLS monitoring at 6-8h and 24h post-dose.",topic:"Venetoclax management",difficulty:"hard"},
{id:"cv12",type:"mcq",stem:"A 52-year-old man presents with lymphocytosis 35 \u00d7 10\u2079/L. Flow: CD5+, CD19+, CD20 bright, CD23\u2212, CD200\u2212, FMC7+, strong SmIg (lambda). CLL score: 1/5. Cytogenetics: t(11;14)(q13;q32). Cyclin D1+. SOX11 negative. No lymphadenopathy, spleen just palpable. Diagnosis?",options:["Typical CLL","Classical HCL","Non-nodal leukaemic mantle cell lymphoma","SMZL"],correctIndex:2,rationale:"Low CLL score (1/5), bright CD20, strong SmIg, CD23\u2212, CD200\u2212, plus t(11;14) and Cyclin D1+ = MCL. SOX11 negativity with leukaemic non-nodal presentation = non-nodal leukaemic MCL \u2014 a more indolent subtype that mimics CLL.",topic:"Differential diagnosis",difficulty:"hard"},
{id:"cv13",type:"mcq",stem:"A 78-year-old woman with CLL (ibrutinib 2 years) develops new palpitations. ECG: irregularly irregular rhythm 128 bpm, absent P waves. BP 108/72 mmHg, haemodynamically stable. Most important consideration?",options:["Ibrutinib has no cardiac effects; investigate other causes","Likely ibrutinib-associated atrial fibrillation; assess bleeding risk and consider rate control","Stop ibrutinib immediately and switch to chlorambucil","Cardiovert immediately under GA"],correctIndex:1,rationale:"AF occurs in 5\u201316% of ibrutinib patients. Management: rate control (beta-blocker preferred; avoid verapamil/diltiazem due to CYP3A4 interaction), cautious anticoagulation (DOACs, avoid warfarin). Consider switching to more selective BTKi (acalabrutinib/zanubrutinib).",topic:"BTKi toxicity",difficulty:"hard"},
{id:"cv14",type:"mcq",stem:"A 66-year-old man with CLL (Binet B) is being considered for obinutuzumab. Before starting treatment, which screening test is most critical to prevent a potentially fatal complication?",options:["HIV serology only","Hepatitis B surface antigen, anti-HBs, and anti-HBc","Tuberculosis IGRA only","CMV PCR only"],correctIndex:1,rationale:"Anti-CD20 antibodies cause profound B-cell depletion and can trigger fulminant HBV reactivation \u2014 even with resolved infection (HBsAg\u2212/anti-HBc+). Full HBV screening mandatory before ANY anti-CD20 therapy. Positive patients need antiviral prophylaxis for \u226512 months after treatment.",topic:"Supportive care",difficulty:"hard"},
{id:"cv15",type:"mcq",stem:"A 45-year-old woman presents with lymphocytosis 4.2 \u00d7 10\u2079/L (clonal B cells 3.8 \u00d7 10\u2079/L). Flow: CD5+, CD19+, CD23+, CLL score 5/5. No lymphadenopathy on CT, no organomegaly, no cytopenias, no symptoms. IGHV mutated, normal FISH. Diagnosis and approximate risk of progression to CLL requiring treatment?",options:["CLL \u2014 immediate treatment needed","Low-count MBL \u2014 ~1% per year progression to CLL needing treatment","High-count MBL \u2014 ~1-2% per year progression","SLL \u2014 tissue biopsy required"],correctIndex:2,rationale:"Clonal B cells <5 \u00d7 10\u2079/L with CLL phenotype and no tissue disease = MBL. This is high-count MBL (0.5\u20135 \u00d7 10\u2079/L) with ~1\u20132% per year progression risk. Regular monitoring (6\u201312 months) recommended, no treatment indicated.",topic:"MBL prognosis",difficulty:"hard"}
],
vemq:[
{id:"ce1",type:"emq",stem:"A 71-year-old man with CLL (unmutated IGHV, del(11q)) on ibrutinib 4 years. Progressive lymphadenopathy despite compliance. Sequencing: BTK C481S and PLC\u03b32 mutations. ECOG 0, no TP53 abnormality. Most appropriate next treatment?",options:["Venetoclax + rituximab (fixed duration)","Continue ibrutinib higher dose","Acalabrutinib (same class switch)","FCR salvage","Idelalisib + rituximab","Chlorambucil + obinutuzumab","Allo-HSCT as immediate next step","CAR-T cell therapy","Radiotherapy to bulky sites","Observation only"],correctIndex:0,rationale:"After covalent BTKi failure with C481S/PLC\u03b32 mutations, class-switch to venetoclax is standard. Another covalent BTKi would fail due to shared resistance mechanism.",topic:"Relapse management",difficulty:"hard"},
{id:"ce2",type:"emq",stem:"A 69-year-old woman with CLL (mutated IGHV, isolated del(13q), Binet C, Hb 94 g/L from marrow failure). Well-controlled hypertension, ECOG 1, CrCl 78 mL/min. Most appropriate first-line treatment?",options:["Venetoclax + obinutuzumab (fixed duration)","Ibrutinib continuous","Acalabrutinib + obinutuzumab","FCR","Bendamustine + rituximab","Chlorambucil + obinutuzumab","Allo-HSCT","CAR-T cell therapy","Radiotherapy","Observation only"],correctIndex:0,rationale:"For older fit patients with mutated IGHV requiring first-line treatment, venetoclax + obinutuzumab offers fixed-duration (12 months) with deep responses and uMRD >75%. Avoids continuous BTKi cardiovascular toxicity.",topic:"First-line treatment",difficulty:"hard"},
{id:"ce3",type:"emq",stem:"A 73-year-old man with CLL develops severe AIHA: Hb 62 g/L, reticulocytes 12%, DAT positive. Prednisolone 1 mg/kg for 3 weeks, Hb only 72 g/L with ongoing haemolysis. Next best step?",options:["Rituximab","Ibrutinib for CLL","Splenectomy","Cyclosporine","Mycophenolate mofetil","Danazol","Red cell exchange","IV immunoglobulin","Plasma exchange","Continue steroids"],correctIndex:0,rationale:"Steroid-refractory warm AIHA in CLL: standard escalation is rituximab (375 mg/m\u00b2 weekly \u00d7 4), achieving 70\u201380% responses. If refractory, CLL-directed therapy (BTKi/venetoclax) is then considered.",topic:"AIHA management",difficulty:"hard"},
{id:"ce4",type:"emq",stem:"A 55-year-old man with classical HCL (BRAF V600E+). Achieved CR with cladribine 2 years ago. Now relapses with same features (pancytopenia, hairy cells, dry tap). Most appropriate treatment?",options:["Repeat cladribine","Vemurafenib + rituximab","Pentostatin","Ibrutinib","Rituximab monotherapy","Splenectomy","Interferon-alpha","Bendamustine + rituximab","Venetoclax","Observation"],correctIndex:1,rationale:"For relapsed classical HCL (BRAF V600E+), vemurafenib + rituximab achieves CR >85% and MRD negativity. This targeted combination is preferred over repeat purine analogue for more durable responses.",topic:"HCL relapse",difficulty:"hard"},
{id:"ce5",type:"emq",stem:"A 60-year-old woman with lymphocytosis. CLL score 2/5. Cytogenetics: t(11;14). Cyclin D1+, SOX11+. CT: generalised lymphadenopathy with largest mesenteric node 4 cm. Most likely diagnosis?",options:["CLL","Non-nodal leukaemic MCL","Classical (nodal) MCL","HCL","SMZL","Follicular lymphoma","LPL/WM","SDRPL","DLBCL","Prolymphocytic leukaemia"],correctIndex:2,rationale:"CLL score 2/5, t(11;14), Cyclin D1+, SOX11+ with significant lymphadenopathy = classical nodal MCL. Non-nodal leukaemic MCL would be SOX11\u2212, CD200+, without significant nodes.",topic:"MCL subtyping",difficulty:"hard"},
{id:"ce6",type:"emq",stem:"A 48-year-old woman with CLL (unmutated IGHV, TP53 mutated, complex karyotype) completed venetoclax + obinutuzumab achieving uMRD CR. Relapsed 18 months after stopping. Fit, no comorbidities. Most appropriate next step?",options:["Re-treat venetoclax + obinutuzumab","BTKi (ibrutinib or zanubrutinib)","FCR","Allo-HSCT directly","Chlorambucil + obinutuzumab","Rituximab monotherapy","CAR-T cell therapy","Observation","Bendamustine-rituximab","Radiotherapy"],correctIndex:1,rationale:"After venetoclax first-line, class-switch to BTKi is standard. Especially in high-risk (TP53/complex karyotype) patients, sequential therapy approach is preferred. Allo-HSCT may be considered later if both classes exhausted.",topic:"Sequential therapy",difficulty:"hard"},
{id:"ce7",type:"emq",stem:"A 67-year-old man with CLL on ibrutinib 18 months develops easy bruising, epistaxis, large subcutaneous haematoma after minor trauma. Platelets 165 \u00d7 10\u2079/L, PT and APTT normal. No anticoagulants used. Most likely explanation?",options:["Immune thrombocytopenia","Ibrutinib-related platelet dysfunction","von Willebrand disease","DIC","Acquired haemophilia","Vitamin K deficiency","Liver failure","TTP","HIT","Factor XIII deficiency"],correctIndex:1,rationale:"Ibrutinib inhibits BTK and TEC family kinases in platelets, impairing collagen-mediated aggregation causing qualitative defect independent of count. Most common bleeding mechanism; avoid warfarin and dual antiplatelet therapy.",topic:"BTKi adverse effects",difficulty:"hard"},
{id:"ce8",type:"emq",stem:"A 63-year-old woman: WBC 12 \u00d7 10\u2079/L with cleaved nuclei (centrocytes/centroblasts). Flow: CD19+, CD10+, BCL6+, CD5\u2212, CD23 weak. FISH: t(14;18)(q32;q21). BM biopsy: paratrabecular lymphoid aggregates. CT: widespread small lymphadenopathy. Diagnosis?",options:["CLL","SMZL","Classical HCL","Non-nodal leukaemic MCL","Follicular lymphoma (leukaemic phase)","LPL/WM","Prolymphocytic leukaemia","DLBCL","Burkitt lymphoma","SDRPL"],correctIndex:4,rationale:"CD10+, BCL6+, t(14;18), cleaved nuclei, paratrabecular marrow infiltration, CD5\u2212/CD23 weak = follicular lymphoma with leukaemic spillover. Paratrabecular pattern is characteristic (CLL is interstitial/diffuse).",topic:"Differential diagnosis",difficulty:"hard"},
{id:"ce9",type:"emq",stem:"A 70-year-old man with CLL (Binet A, mutated IGHV, no treatment) develops herpes zoster (two dermatomes). IgG 4.8 g/L. Two pneumonia episodes requiring hospitalisation in the past year. Most appropriate supportive measure?",options:["Prophylactic aciclovir only","Immunoglobulin replacement therapy","Start CLL-directed therapy","Pneumococcal vaccination only","Prophylactic co-trimoxazole","IV rituximab","Thalidomide","G-CSF prophylaxis","Tonsillectomy","No action needed"],correctIndex:1,rationale:"Symptomatic hypogammaglobulinaemia (IgG 4.8 g/L + recurrent serious infections) warrants IgG replacement (IVIg/SCIg). Target IgG trough >5 g/L. CLL therapy not indicated (Binet A, no active disease).",topic:"Supportive care",difficulty:"hard"},
{id:"ce10",type:"emq",stem:"A 76-year-old man with CLL (10 years, active surveillance, Binet A) has routine skin check revealing a 2 cm firm violaceous forearm nodule. Biopsy: Merkel cell carcinoma. CLL is stable. How should this be contextualised?",options:["Coincidental finding","CLL patients have substantially increased Merkel cell carcinoma risk","Merkel cell carcinoma causes CLL","Richter transformation as skin disease","CLL skin infiltration","Drug reaction from CLL therapy","Metastatic DLBCL to skin","Secondary MDS","EBV-related LPD","Squamous cell carcinoma misdiagnosed"],correctIndex:1,rationale:"CLL patients have 5\u201310 fold increased Merkel cell carcinoma risk due to chronic immune dysregulation. CLL has 10\u201315% rate of second malignancies. Requires standard oncological management independent of CLL.",topic:"Second malignancies",difficulty:"hard"}
]};

// === QUIZ ENGINE ===
let currentTab='mcq',attempt=null;
const letters='ABCDEFGHIJ';

function shuffle(arr){const a=[...arr];for(let i=a.length-1;i>0;i--){const j=Math.floor(Math.random()*(i+1));[a[i],a[j]]=[a[j],a[i]]}return a}

function buildAttempt(){
function shuffleQ(bank){return shuffle(bank.map(q=>{
const idx=q.options.map((_,i)=>i);const si=shuffle(idx);
return{...q,options:si.map(i=>q.options[i]),correctIndex:si.indexOf(q.correctIndex)};
}));}
return{id:crypto.randomUUID(),start:new Date().toISOString(),mcq:shuffleQ(QUIZ_BANK.mcq),emq:shuffleQ(QUIZ_BANK.emq),vmcq:shuffleQ(QUIZ_BANK.vmcq),vemq:shuffleQ(QUIZ_BANK.vemq),answers:{},finished:false};
}

function renderQuiz(){
const qs=attempt[currentTab];
const c=document.getElementById('quizContainer');
c.innerHTML='';
document.getElementById('resultsCard').classList.remove('show');
document.getElementById('finishBtn').style.display='inline-block';
qs.forEach((q,i)=>{
const div=document.createElement('div');div.className='q-card';div.id='q-'+q.id;
div.setAttribute('role','group');div.setAttribute('aria-label','Question '+(i+1));
const diffClass=q.difficulty==='easy'?'q-diff-easy':q.difficulty==='medium'?'q-diff-medium':'q-diff-hard';
div.innerHTML=`
<div class="q-meta"><span class="q-topic">${q.topic}</span><span class="${diffClass}">${q.difficulty}</span></div>
<div class="q-stem"><span class="mono" style="color:var(--teal);margin-right:6px">Q${i+1}.</span>${q.stem}</div>
<div class="q-options" role="radiogroup" aria-label="Answer options">${q.options.map((o,oi)=>`
<button class="q-opt" data-qid="${q.id}" data-oi="${oi}" onclick="selectAnswer('${q.id}',${oi})" role="radio" aria-checked="false" tabindex="0">
<span class="q-opt-letter">${letters[oi]}</span><span>${o}</span>
</button>`).join('')}</div>
<div class="q-feedback" id="fb-${q.id}"></div>`;
c.appendChild(div);
});
updateProgress();
}

function selectAnswer(qid,oi){
if(attempt.answers[qid]!==undefined)return;
attempt.answers[qid]=oi;
const qs=[...attempt.mcq,...attempt.emq,...attempt.vmcq,...attempt.vemq];
const q=qs.find(x=>x.id===qid);
const correct=oi===q.correctIndex;
const btns=document.querySelectorAll(`[data-qid="${qid}"]`);
btns.forEach(b=>{
b.classList.add('answered');
const boi=+b.dataset.oi;
if(boi===q.correctIndex)b.classList.add('correct');
if(boi===oi&&!correct)b.classList.add('incorrect');
b.setAttribute('aria-checked',boi===oi?'true':'false');
});
const fb=document.getElementById('fb-'+qid);
fb.className='q-feedback show '+(correct?'correct-fb':'incorrect-fb');
fb.innerHTML=`<strong>${correct?'Correct':'Incorrect'}</strong><br>${q.rationale}`;
updateProgress();
}

function updateProgress(){
const qs=attempt[currentTab];
const answered=qs.filter(q=>attempt.answers[q.id]!==undefined).length;
const pct=Math.round(answered/qs.length*100);
document.getElementById('progressBar').style.width=pct+'%';
if(answered===qs.length)document.getElementById('finishBtn').style.display='inline-block';
}

function switchTab(tab){
currentTab=tab;
document.getElementById('tabMCQ').classList.toggle('active',tab==='mcq');
document.getElementById('tabEMQ').classList.toggle('active',tab==='emq');
document.getElementById('tabVMCQ').classList.toggle('active',tab==='vmcq');
document.getElementById('tabVEMQ').classList.toggle('active',tab==='vemq');
renderQuiz();
}

function startEMQ(){switchTab('emq');document.getElementById('quiz-zone').scrollIntoView({behavior:'smooth'})}

function finishQuiz(){
attempt.finished=true;attempt.end=new Date().toISOString();
const mcqScore=calcScore(attempt.mcq);
const emqScore=calcScore(attempt.emq);
const vmcqScore=calcScore(attempt.vmcq);
const vemqScore=calcScore(attempt.vemq);
const total=mcqScore.correct+emqScore.correct+vmcqScore.correct+vemqScore.correct;
const totalQ=attempt.mcq.length+attempt.emq.length+attempt.vmcq.length+attempt.vemq.length;
const pct=Math.round(total/totalQ*100);
const mcqPct=Math.round(mcqScore.correct/attempt.mcq.length*100);
const emqPct=Math.round(emqScore.correct/attempt.emq.length*100);
const vmcqPct=Math.round(vmcqScore.correct/attempt.vmcq.length*100);
const vemqPct=Math.round(vemqScore.correct/attempt.vemq.length*100);

document.getElementById('resScore').textContent=pct+'%';
document.getElementById('resMCQ').textContent=mcqPct+'%';
document.getElementById('resEMQ').textContent=emqPct+'%';
document.getElementById('resVMCQ').textContent=vmcqPct+'%';
document.getElementById('resVEMQ').textContent=vemqPct+'%';
document.getElementById('resOverall').textContent=pct+'%';

let award='';
if(pct===100)award='You are CLL Master! ðŸ†ðŸ‘‘';
else if(pct>=90)award='Gold Medal! ðŸ¥‡';
else if(pct>=80)award='Trophy! ðŸ†';
else if(pct>=70)award='Pass âœ“';
else award='Keep going!';
document.getElementById('resAward').textContent=award;

const gd=document.getElementById('resGuidance');
if(pct<70){
const domains={};
[...attempt.mcq,...attempt.emq,...attempt.vmcq,...attempt.vemq].forEach(q=>{
if(!domains[q.topic])domains[q.topic]={c:0,t:0};
domains[q.topic].t++;
if(attempt.answers[q.id]===q.correctIndex)domains[q.topic].c++;
});
const weak=Object.entries(domains).map(([t,s])=>({t,p:s.t?Math.round(s.c/s.t*100):0})).sort((a,b)=>a.p-b.p).slice(0,3);
gd.style.display='block';
gd.innerHTML=`<strong>You are building strong foundations.</strong> Focused revision will rapidly improve your score.<br><br><strong>Focus areas:</strong><ul>${weak.map(w=>`<li>${w.t} (${w.p}%)</li>`).join('')}</ul><br><em>Guidance from Dr Abdul Mannan</em>`;
}else{gd.style.display='none'}

document.getElementById('resultsCard').classList.add('show');
document.getElementById('finishBtn').style.display='none';
saveHistory({id:attempt.id,date:attempt.start,mcq:mcqPct,emq:emqPct,vmcq:vmcqPct,vemq:vemqPct,overall:pct,award});
document.getElementById('resultsCard').scrollIntoView({behavior:'smooth'});
}

function calcScore(qs){let c=0;qs.forEach(q=>{if(attempt.answers[q.id]===q.correctIndex)c++});return{correct:c,total:qs.length}}

function saveHistory(rec){
const k='cll_quiz_history';
const h=JSON.parse(localStorage.getItem(k)||'[]');
h.unshift(rec);
localStorage.setItem(k,JSON.stringify(h.slice(0,10)));
}

function resetQuiz(){attempt=buildAttempt();renderQuiz()}
function showAllQuestions(){document.getElementById('resultsCard').classList.remove('show');renderQuiz()}

function filterModules(val){
const v=val.toLowerCase();
document.querySelectorAll('.module').forEach(m=>{
m.style.display=m.textContent.toLowerCase().includes(v)?'':'none';
});
}

// INIT
attempt=buildAttempt();
renderQuiz();

// Sticky nav active state
const observer=new IntersectionObserver(entries=>{
entries.forEach(e=>{
if(e.isIntersecting){
document.querySelectorAll('.sticky-nav a').forEach(a=>a.classList.remove('active'));
const link=document.querySelector(`.sticky-nav a[href="#${e.target.id}"]`);
if(link)link.classList.add('active');
}
});
},{threshold:0.3});
document.querySelectorAll('.module,.quiz-zone').forEach(s=>observer.observe(s));
</script>
</body>
</html>
